 
ClinicalTrials.gov Posted Document Cover Page 
Clinical Study Protocol 
 
PROTOCOL TITLE:  A M ulticenter, Randomized, Double-blind, Placeb O-controlled, 
Parallel-group Study to E Valuate the E fficacy and Safety of 
JTE-051 Administered for 12 Weeks to Subjects with Active 
Rheumatoid A rthritis (MOVE-RA)  
PROTOCOL NUMBER:  AE051-G-13-003  
PROTOCOL DATE:  [ADDRESS_1066893] NUMBER: [STUDY_ID_REMOVED] 
 
  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Cover Page  
Akros Pharma Inc.  
Clinical Protocol  
PROTOCOL TITLE:  A Multicenter, Randomized, Double-blind, 
Placeb O-controlled, Parallel -group Study to E Valuate the 
Efficacy  and Safety of JTE -051 Administered for 12 Weeks to 
Subjects with  Active  Rheumatoid A rthritis  (MOVE -RA) 
PROTOCOL NUMBER:  AE051-G-13-003 
DATE:  24 March 2016  
IND NUMBER:   
EUDRACT NUMBER  2015-003140-39 
SPONSOR:  Akros Pharma Inc.  
[ADDRESS_1066894]:  
Akros Pharma Inc.  
302 Carnegie Center, Suite 300 Princeton, NJ  [ZIP_CODE]  
 
MEDICAL MONITOR:  
 
 
Confidentiality Statement  
The confidential information in this document is provided to you as an Investigator or consultant for review by [CONTACT_132334] u, your 
staff, and the applicable Institutional Review Board/Independent Ethics Committee (IRB/IEC). Your acceptance of this 
document constitutes agreement that you will not disclose the information contained herein to others or use the information for any  purpose other than the performance of your obligations pursuant to your and/or your employer’s 
separate agreement with us, our affiliate or our contractor, as the case may be, without prior written authorization from Akros Pharma Inc.  (Akros). 
 
1 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Signature  [CONTACT_776882]:  AE051-G-13-003 
Protocol Number:  A Multicenter, Randomized, Double -blind, Placeb O-controlled, 
Parallel -group Study to E Valuate the Efficacy  and Safety of 
JTE-051 Administered for 12 Weeks to Subjects with Active  
Rheumatoid A rthrit is (MOVE -RA) 
The signatures below indicate approval of the protocol. 
Sponsor 
Representative   
   
 
 
  Date  
Sponsor 
Statistician     
 
  Date  
 
  
Investiga tor's Statement of Agreement : 
 I acknowledge possession of the JTE-051 Investigator’s Brochure  (IB) and this protocol . 
Having fully reviewed all the information provided, I consider it ethically justifiable to give the study drug to subjects according to t he agreed protocol . I will conduct the study 
in full accordance with this protocol and all applicable laws and regulations, including but not limited to current Good Clinical Practices.  
 
 
Investigator     
 (Signature)  
  
  Date  
 (Printed Name)    
2 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066895] of Abbreviations and Definitio n of Terms  ................................................................. 6  
Protocol Synopsis ............................................................................................................. 11  
1. Introduction .............................................................................................................. 17  
1.1. Background ..................................................................................................... 17  
1.1.1.  Rheumatoid Arthritis  ................................................................................ 17  
1.1.2.  Treatment of Rheumatoid Arthritis  ........................................................... 17  
1.1.3.  Interleukin-2-inducible T- cell Kinase ....................................................... 18  
1.2. JTE-051 ............................................................................................................ 19  
1.2.1.  Nonclinical Studies  ................................................................................... 19  
 
2 Study Objectives  ....................................................................................................... 32  
3 Investigational Plan  ................................................................................................. 32  
3.1. Number of Sites and Subjects  ........................................................................ 32  
3.2. Study Design .................................................................................................... 32  
3.3. Selection of Study Population ........................................................................ 33  
3.3.1.  Inclusion Criteria ....................................................................................... 33  
3.3.2.  Exclusion Criteria  ..................................................................................... 34  
3.4. Removal of Subjects f rom the Study  ............................................................. 39  
3.5. Study Procedures  ............................................................................................ 41  
3.5.1.  Screening Period  ....................................................................................... 44  
3.5.2.  Double- blind Treatment Period  ................................................................ 44  
3.5.3.  Follow-up Period ...................................................................................... 45  
3.5.4.  Study Restrictions  ..................................................................................... 46  
 
3.5.6.  Procedure Definitions ............................................................................... 52  
3.5.7.  Clinical Institutions and Laboratories ....................................................... 60  
3.6. Adverse Events  ................................................................................................ 61  
3.6.1.  Safety Definitions  ..................................................................................... 61  
3.6.2.  Assessing Adverse Events ........................................................................ 62  
3.6.3.  Reporting Adverse Events  ........................................................................ 64  
3.7. Identification of Treatments  .......................................................................... 66  
3.7.1.  Method of Assigning Subjects to Treatment Groups ................................ 66  
3 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066896] Population for Analysis  ................................................................ 69  
3.8.2.  Interim Analysis  ........................................................................................ 70  
3.8.3.  Efficacy Analyses  ...................................................................................... 70  
3.8.4.  Safety Analyses  ......................................................................................... 74  
3.8.5.  Pharmacokinetic Analyses  ........................................................................ 74  
3.9. Quality Control and Quality Assurance ....................................................... 75  
4 Investigator Obligations ........................................................................................... 75  
4.1. Institutional Review/Independent Ethics Committee  .................................. [ADDRESS_1066897] Consent  ............................................................................................... 76  
4.3. Data Collection ................................................................................................ 77  
4.3.1.  Case Report Forms  .................................................................................... 77  
4.3.2.  Source Documents .................................................................................... 77  
4.4. Adherence to Protocol  .................................................................................... 77  
4.5. Reporting Adverse Events  .............................................................................. 77  
4.6. Investigator’s Final Report  ............................................................................ 77  
4.7. Records Retention  ........................................................................................... 77  
4.8. Confidentiality  ................................................................................................. 78  
4.9. Publications  ..................................................................................................... 78  
5 Study Management .................................................................................................. 79  
5.1. Monitoring  ....................................................................................................... 79  
5.2. Management of Protocol Amendments and Deviations .............................. 79  
5.3. Study Termination .......................................................................................... 80  
5.4. Sponsor’s Final Report  ................................................................................... 80  
6 References  ................................................................................................................ 81  
7 Appendices  ................................................................................................................ 84  
Appendix 1.  ACR/EULAR Classification Criteria for Rheumatoid Arthritis  85 
 
Appendix 3.  Numeric Rating Scale Templates  ................................................... 87  
4 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Appendi x 4. Health Assessment Questionnaire ................................................. 88  
Appendix 5.  Efficacy Endpoints Calculation ..................................................... 94  
Numeric ACR (ACR -N) Index  ............................................................................... 94  
The ACR20/50/70 Response Rate  .......................................................................... 94  
Simple Disease Activity Index  ................................................................................ 95  
Clinical Disease Activity Index  .............................................................................. 95  
Disease Activity Score (DAS) [ADDRESS_1066898] of Figures  
 
Figure 1.  Planned Study Schema  .................................................................................... 41  
 
Figure 3.  Tender and Swollen Joint Counts (68/66)...................................................... 52  
Figure 4.  Tender and Swollen Joint Counts (28)  ........................................................... [ADDRESS_1066899] of Tables  
 
Table 1.  Planned Schedule of Study Procedures .......................................................... 42  
Table 2.  Companion Aids/Device Items for HAQ -DI Categories  ............................... 93  
 
 
5 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066900] OF ABBREVIATION S AND DEFINITION OF TERMS  
Abbreviation  Definition  
Ab Antibody  
ACPA  Anti–citrullinated protein antibody  
ACR  American College of Rheumatology  
ACR20  Percentage of subjects achieving at least 20% improvement from baseline 
in tender and swollen joint counts and at least 20% improvement in [ADDRESS_1066901] 50% improvement  from baseline  
in tender and  swollen joint counts and at least 50% improvement in [ADDRESS_1066902] 70% improvement from baseline 
in tender and  swollen joint counts and at least 70% improvement in 3 of 
the 5 remaining ACR core set measures  
ACR -N Numeric ACR: the lowest percentage improvement from ba seline of 3 
measures: tender joint count, swollen joint count and median improvement of the remaining [ADDRESS_1066903] cancer resistance protein  
BMI Body mass index  
6 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Abbreviation  Definition  
BUN  Blood urea nitrogen  
CABG  Coronary Artery By[CONTACT_776807] -induced arthritis  
CDAI  Clinical Disease Activity Index  
CFR  Code of Federal Regulations  
CI Confidence interval  
CIA Collagen -induced arthritis  
CL_F  Apparen t oral clearance of drug following extravascular administration  
Cmax Maximum c oncentration  
COX  Cyclooxygenase  
CRF  Case r eport form 
CRP  C-reactive protein   
CTCAE  Common Terminology Criteria for Adverse Events  
Ctrough Trough concentration  
CV%  Coeffici ent of variation  
CYP  Cytochrome P450  
DAS  Disease Activity Score  
DB Double -blind  
DDI Drug -drug interaction  
DIP Distal interphalangeal  
DMARDs  Disease -modifying anti -rheumatic drugs  
ECG  Electrocardiogram  
EGF  Epi[INVESTIGATOR_776790]3 Fms-like tyrosine kinase -3 
FSH Follicle -stimulating hormone  
GCP  Good Clinical Practice  
GEE  Generalized estimating equation  
eGFR  Estimated glomerular filtration r ate 
7 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Abbreviation  Definition  
HAQ -DI Health Assessment Questionnaire Disability Index  
HBc Hepatitis B core 
HBsAg  Hepatitis B virus s urface antigen  
HCV  Hepatitis C v irus 
HDL -C High -density lipoprotein cholesterol  
HEENT  Head, Ears, Eyes, Nose, Throat  
βhCG  Human chorionic g onadotropin  
hERG  Human ether -a-go-go related  gene 
HIV Human i mmunodeficiency virus 
hs-CRP  High -sensitivity C -reactive protein  
IB Investigator’s brochure  
ICH International Conference on Harmonisation  
IC50 Half-maximal  inhibitory concentration  
IEC Independent Ethics Committee  
IFNγ  Interferon γ  
IL-[ADDRESS_1066904]  Modification  of Diet in Renal Disease  
MedDRA  Medical Dictionary for Regulatory Activities 
8 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Abbreviation  Definition  
MMF  Mycophenolate mofeti  
MMP  Matrix metalloproteinase   
MOA  Mechanism of action  
MTP  Metatarsophalangeal  
MTX  Methotrexate  
N/A Not applicable  
 
NRS  Numerical Rating Scale  
NSAIDs  Non-steroidal anti -inflammatory drugs  
NYHA  [LOCATION_001] Heart Association  
PGA  Physician’s Global Assessment  
P-gp P-glycoprotein  
PI [INVESTIGATOR_776791] (s)   
PP Per protocol  
[COMPANY_003] Purified Protein Derivative  
PR Interval from beginning of the P wave to the beginning of the QRS 
complex in the frontal plane 
PT Prothrombin Time  
PTCA  Percutaneous Transluminal Coronary Angioplasty  
OAT  Organic  anion transporter  
OATP  Organic anion t ransporting polypeptide  
OCT  Organic cation transporter  
QD Once daily  
QOL  Quality of life  
QRS   Duration of QRS complex in the frontal plane   
QT  Interval from beginning of the QRS complex to end of the T  wave in the 
frontal plane  
QTcF  Fridericia -corrected QT Interval  
RA Rheumatoid Arthritis  
RF Rheumatoid Factor  
9 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066905]’s Global Assessment  
SNRIs  Serotonin -norepi[INVESTIGATOR_776792]  
t1/2 Elimination half -life associated with the terminal slope (λz) of a 
semilogarithmic concentration -time curve  
TCR  T cell receptor  
TDI Time -dependent inhibition  
TEAE  Treatment -emergent adverse event  
TIA Transient ischemic attack  
tmax Time to reach peak  or maximum concentration following drug 
administration   
TNF -α Tumor necrosis factor -α  
TNF -RI Tumor necrosis factor receptor I  
TSH  Thyroid stimulating hormone  
ULN  Upper limit of normal 
USP [LOCATION_002] Pharmacopeia   
VCAM -1 Vascular cell adhesion molecule -1  
VEGF -A Vascular endothelial growth factor  A  
V_F Apparent volume of distribution following extravascular administration  
YKL -40 Human cartilage glycoprotein 39  
10 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Protocol Synopsis  
 
STUDY TITLE A Multicenter, Ran domized, Double -blind, 
Placeb O-controlled, Parallel -group Study to E Valuate the 
Efficacy and Safety of JTE -051 Administered for 12 Weeks 
to Subjects with Active R heumatoid A rthritis  (MOVE -RA) 
PROTOCOL NUMBER AE051-G-13-[ADDRESS_1066906]: 
• Up to a 28- day Screening P eriod  
• A 12-week double- blind (DB) Treatment Period  
• Approximately a 4 -week Follow-up Period  
STUDY OBJECTIVES  • To evaluate the clinical efficacy of JTE -051 in subjects 
with activ e rheumatoid arthritis  receiving background 
non-biologic disease- modifying anti -rheumatic drug  
therapy . 
• To evaluate the safety and tolerability of JTE -051 
administered for 12 weeks in subjects with active 
rheumatoid arthritis receiving background non-biologic 
disease-modifying anti-rheumatic drug therapy.  
• To evaluate the pharmacokinetics (PK) of JTE -051 in 
plasma of subjects with active rheumatoid arthritis .  
STUDY DESIGN 
 This is a multicenter, randomized, double -blind, 
placebo -controlled, parallel -group, 12-w eek study in biologic 
and kinase inhibitor treatment-naive rheumatoid arthritis 
(RA) subjects  on stable  diseas e-modifying anti -rheumatic 
drug ( DMARD) therapy, including methotrexate ( MTX) . 
Eligible subjects  will be randomized at Visit 2 to receive 
JTE- 051 50 mg, 100 mg, 150 mg, 200 mg  or placebo once 
daily  (QD)  for 12  weeks. Subjects  will continue to receive up 
to two non-biologic DMARDs, including MTX , throughout 
the study (at a stable background dose and route of 
administration for at least 12 weeks prior to Visit 2  and 
throughout the study)  and will return for a Follow -up Visit 
approximately four weeks after the last dose of study drug is 
administered . Randomization will be stratified by 
[CONTACT_776808]-sensitivity 
C-reactive protein (hs- CRP ). 
11 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
NUMBER OF 
SUBJECTS TO BE ENROLLED AND RANDOMI ZED A sufficient number of subjects  will be screened to ensure 
the randomization ( in a 1:1:1:1:1  ratio) of approximately 
250 subjects (50 subjects  per treatment group). 
KEY ELIGIBILITY  
CRITERIA • Males and females, 18 to 75 years of age  (inclusive) at the 
time of the Screening Visit; 
• A diagnosis of RA prior to the Screening Visit, based on 
the American College of Rheumatology  (ACR )/European 
League Against Rheumatism ( EULAR ) 2010 
Classifica tion Criteria; 
• Active disease despi[INVESTIGATOR_776793]-biologic DMARDs, including MTX at both the 
Screening and Baseline Visits  (Visits 1 and 2) , as defined 
by [CONTACT_17588]: 
 ≥6 out of 68 tender joints AND 
 ≥6 out of 66 swollen joints;  
• Screening hs -CRP ≥1.2 x upper limit of normal (ULN), 
based on the central laboratory values;  
• Background treatment with up to two non- biologic 
DMARDs including MTX (mandatory) and one of the 
following medications  (optional) : sulfasalazine ≤ 3 g/day , 
hydroxychloroquine ≤400 mg/day  or c hloroquine: 
≤250 mg/day  at the time of  the Screening Visit; 
 The MTX dosage must be  15-25 mg/week  (or the 
maximum documented tolerated dose  for the 
subject , not  <10 mg/week) and all background 
therapy must be stable , defined as no change in 
dose or route of administration for ≥ 12 weeks  
prior to the Randomization Visit (Visit 2 ). 
• No p rior/current exposure to biologic and/or kinase  
inhibitor therapy;  
 
 
 
12 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066907]         
(STUDY DRUG), FORMULATION,  
DOSAGE,  ROUTE AND TIME OF ADMINISTRATION  
 
JTE-[ADDRESS_1066908] been completed (except for 
Visit 6, when no study drug will be administered).   
REFERENCE 
PRODUCT          
(STUDY DRUG) , 
FORMULATION,  
DOSAGE,  
ROUTE AND TIME OF ADMINISTRATION  
Placebo  
Tablets (identical in a ppearance to the JTE-051 tablets )  
Not applicable (N/A)   
Oral administration  for [ADDRESS_1066909] been completed (except for 
Visit 6, when no study drug will be administered).   
EVALUATION 
CRITERIA Primary Efficacy Parameters  
• Percentage of subjects achieving at least 20% 
improvement from baseline in tender and swollen joint 
counts and at least 20% improvement from baseline in 3 
of the 5 remaining ACR core set measures  (ACR20 
response rate) at end of treatment (EOT)  
Secondary Efficacy Parameters   
(will be evaluated at Weeks 2, 4, 8, 12 and 16 unless 
otherwise stated)  
• Percentage of subjects achieving at least 20, 50 and 70% 
improvement from baseline in tender and swollen joint 
counts and at least 20, 50 and 70% improvement from 
baseline in 3 of the 5 remaining ACR -core set measures, 
respectively  (i.e., ACR20/50/70 response rate)  
13 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
EVALUATION 
CRITERIA, Cont. Secondary Efficacy Parameters, Cont.  
• Change from baseline in Simplified Disease Activity 
Index (SDAI)  
• Percent age of subjects  who achieved  remission based on 
SDAI (≤3.3)  
• Percent age of subjects who achieved low diseas e activity 
based on SDAI (≤11)  
• Change from baseline in Clinical Disease Activity Index 
(CDAI)  
• Percent age of subjects  who achieved remission  based on 
CDAI (≤2.8)  
• Percent age of subject s who achieved  low disease activity 
based on CDAI (≤10)  
• Percentage of subjects in Boolean Remission  
• Change from baseline in Disease Activity Score (DAS)  
based on hs- CRP ( DAS28 -CRP ) 
• Percentage of subject s with DAS28 -CRP of <2.6 
• Percentage of subjects with D AS28 -CRP of <3.2 
• Percent age of subjects with good EULAR response at 
Week  12 
• Percent age of subjects with moderate EULAR response at 
Week  12 
• The lowest percentage change from baseline of 
3 measures: tender joint count, swollen joint count and 
median change of the remaining 5 core measures  
(numeric ACR  [ACR -N] index)  
• Change from baseline in the Health Assessment 
Questionnaire Disability Index (HAQ -DI)  
• Change from baseline in the number of tender and 
swollen joint counts (68/66 joints will be counted)  
• Change from baseline in subject pain score by [CONTACT_319090] (NRS)  
• Change from baseline in subject global assessment  (SGA)  
of disease activity by [CONTACT_37224]  
• Change from baseline in physician global assessment 
(PGA) of disease activity by [CONTACT_37224]  
• Change from baselin e in hs- CRP  
14 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
EVALUATION 
CRITERIA, Cont.  
 
 
Safety  Parameters  
• The number of subjects with adverse events  (AEs), type 
and severity of AEs , change from  baseline in the safety 
laboratory, vital sign and electrocardiogram (ECG) 
parameters  
Pharmacokinetic (PK) Parameters  
• Trough plasma levels of JTE-051  
• The relationship between the JTE-0 51 dose (exposure) 
and response may be assessed (exploratory)  
STATISTICAL 
METHODS  For the primary efficacy parameter (ACR20 at EOT), the 
Fisher’s exact test will be used to compare each JTE -[ADDRESS_1066910] will be computed . 
For dichotomous secondary efficacy parameters, similar 
analyses as the primary efficacy parameter will be used by 
[CONTACT_7206]. 
 
 
 
15 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066911].  
All analyses wi ll be performed at the  two-sided α= 5% 
significance level. No formal multiple comparison 
adjustment will be made . The estimated treatment effect 
(relative to placebo) from the model , along with a two -sided 
95% confidence interval ( CI) and p-value, will be tabulated  
where appropriate.  
Descriptive statistics of efficacy parameter s over time will be 
presented  by [CONTACT_3148] . They will include the number of 
subjects (N) , arithmetic mean, standard deviation (SD), 
median, minimum and maximum  for continuous parameter s, 
and in frequency tabulation form for dichotomous 
parameters.  
The Newcombe’s  CI of the rate difference between JTE -051 
dose and placebo will be computed when performing the 
Fisher’s exact test. Graphical presentations of the treatment 
profile may be depi [INVESTIGATOR_1230]. Sensitivity analysis, model fit 
assessment may be conducted and data transformation may 
be employed if appropriate. 
Descriptive statistics of efficacy parameter s over time will be 
presented  by [CONTACT_3148] .  
With respect to the safety data analysis, d escriptive statistics 
of vital signs, ECG parameters, and clinical laboratory data will be presented by [CONTACT_3148] . 
Potentially clinically 
significant values for vital signs, ECG, and laboratory data 
will be flagged in data listings and may be summarized as 
appropriate. 
For PK data, descriptive statistics of the trough plasma 
concentration of JTE-051 will be presented by [CONTACT_3148].  
 
16 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
1. I NTRODUCTION 
1.1. Background 
1.1.1.  Rheumatoid Arthritis  
Rheumatoid arthritis  (RA) is a systemic autoimmune disease of unknown cause 
characterized by [CONTACT_776809], joint tenderness and synovial joint 
destruction that leads to pain and disability.1 Approximately 1% of the world’s population 
is considered to be suffering from the disease2 and t he number of patients is estimated to 
be approximately 1.3 million in the US.3 Females are more likely to suffer from the 
disease, with a reported ratio of male to female patients of 1:2.5. The disease can occur at 
any age, but it is most common among those aged 40 to 70 years , its incidence increasing 
with age.  
In rheumatoid arthritis, abnormal a
ctivation of various inflammatory cells such as T cel ls 
and macrophages causes and exacerbates chronic synovitis. Patients mostly complain of 
morning stiffness as an initial symptom. The disease is characterized by [CONTACT_776810], hands and kne es, leading 
to the development of pai n, swelling associated with synovial fluid retention and local 
warmth . The inflammatory symptoms  are mostly experienced  in the early stage followed 
by [CONTACT_776811], which lead to the destruction of c artilage and bone , 
with deformation of the joints over time , finally causing severe dysfunction. When the 
disease is highly active, various clinical symptoms s uch as general malaise, pyrexia, and 
anemia are observed as non -joint- related symptoms. It is kno wn that th
ese symptoms 
markedly impair the activities of daily life and finally worsen life prognosi s. It has been 
reported  that insufficient treatment shortens the life of patients with rheumatoid arthritis 
by 10 to 15 years compared with that of healthy individuals .4  
1.1.2.  Treatment of Rheumatoid Arthritis  
The treatment of rheumatoid arthritis aims to maintain the physical functions of the patients and improve their quality of life (QOL) through control of symptoms and prevention of joint destruction.
5 To achieve these aims, drug treatments from an early 
stage of the disease based on the background of appropriate nonmedical therapi[INVESTIGATOR_776794].
6,7 Currently, as therapeutic agents , disease-modifying 
anti-rheumatic drugs (DMARDs), non- steroidal anti- inflammatory drugs (NSAIDs), oral 
use and intraarticular injection of steroids, and biological agents are used. 
Disease- modifying anti -rheumatic drugs  that can inhibit progression of the pathological 
conditions play a central role in the treatment. Methotrexate (MTX) is prescribed as the standard therapy and immunosuppressive drugs are prescribed as switch or combination therapy. D isease-modifying anti-rheumatic drugs alleviate pain and swelling by [CONTACT_776812], but their efficacy is not sufficient, leaving some non-responders and those with a reduced response without  relief. These drugs  may also be able to inhibit 
the joint destruction, but their inhibit ory effect on the progression of destruction of the 
cartilage and bone is not sufficient in the absence of remission. Since DMARDs are slow -
acting, it takes a long time to improve the QOL, and the pathological condition may be allowed to progress if judgment to change the drug for non- responders is delayed. Since 
17 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
rheumatoid arthritis has a chronic course, long -term therapi[INVESTIGATOR_776795], 
however, very often, it  is difficult to continue sufficient treatment due to adverse events  
(AEs) such as disorders in gastrointestinal tract associated with NSAID use, blood and 
liver AEs  caused by [CONTACT_776813], as well as osteoporosis associated with steroids. Recently, 
it has been demonstrated that biological agents can quickly alleviate arthritis symptoms 
and suppress progression of joint destruction by [CONTACT_776814] -α (TNF -α) and i nterleukin- 6 (IL -6).
8-[ADDRESS_1066912] efficiency are desired.  
1.1.3.  Interleukin-2- inducible T -cell Kinase  
Interleukin-2- inducible T -cell kinase (ITK) is a non- receptor protein tyrosine kinase that 
is mainly expressed in T  cells, mast cells, and natural killer cells.  In the T cells, the 
molecule plays a role in transmitting stimulation triggered by  [CONTACT_776815] T cell 
receptor ( TCR ) located  on the cell membrane.
12 When antigen is presented with the major 
histocompatibility complex on the antigen -presenting cells such as dendritic cells and 
macrophages, T cells are activated by [CONTACT_776816]. As a resul t of 
activation,  T cells produce cytokines such as interleukin -2 (IL-2), interleukin -17 (IL-17) 
and interferon γ (IFNγ ) and accelerate their own proliferation. It is also considered that 
T cells are significantly  involved in the development of tissue inflammation and damage 
by [CONTACT_776817]. Findings that indicate a 
relationship between ITK and pathological changes have been reported . T cells obtained 
from ITK -knockout mice could not show IL -[ADDRESS_1066913] inflamma tion induced by [CONTACT_15195]: the production 
of various cytokines in the T cells in lymphoid tissues, the infiltrative inflammatory cell 
counts in the airway, and the secretion of airway mucus .[ADDRESS_1066914] that 
ITK may be involved in the development of pathological changes in autoimmune diseases, transplant rejection and allergic diseases of which the onset and exacerbation are caused by [CONTACT_776818].  
 
 
 
18 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
1.2. JTE-
051 
A brief summary of the nonclinical findings to date is included below. Additional details 
are described in the JTE -051 Investigator’s Brochure (IB). 
1.2.1.  Nonclinical Studies  
19 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
20 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
21 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
 
 
22 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
23 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
24 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
25 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
 
26 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
1.3. Justification of Study Population and Dose Selection  
Justification for Study P opulation 
 
 
P
atients with a diagnosis of RA, based on the American College of R heumatology 
(ACR )/European League against Rheumatism ( EULAR ) 2010 Classification C riteria23 
(see Appendix 1) , that are MTX -insuffi cient responders, i.e., have active R A (defined by 
[CONTACT_776819]) despi[INVESTIGATOR_776796] 12 weeks with 
MTX (and up to one  additional non- biologic DMARD) will be enrolled in this study (for 
the purpose of the study,  RA patients will be referred to as “subjects” throughout the 
protocol). The inclusion/exclusion criteria and  the restrictions set in this study are based 
on its objectives, i.e., to demonstrate  the clinical efficacy of the compound and to 
evaluate safety and tolerability of JTE -051 in patients with RA , the stage in development 
(i.e., early Phase [ADDRESS_1066915] to evaluate clinical efficacy in RA) and the 
nonclinical/clinical characteristics of JTE -051, based on the data  available to date. Efforts 
have been made to take into account feasibility and enrollment- related considerations 
while maintaining the scientific integrity of the study  and minimizing the risks for the 
study subjects. 
Briefly, from an efficacy perspective, s tudy s ubjects must have not been exposed to 
biologic or kinase inhibitor therapy in order to minimize the variability in the efficacy 
response due to prior exposure to these immunosuppressive/immunomodulator agents in 
this “first- in patient” study. Additionally, i n order to be eligible, subjects would have to 
have high-sensitivity C -reactive protein ( hs-CRP ) levels >1. 2 x the upper limit of normal 
(ULN) at study entry, to confirm  a suffic ient level of disease activity and to allow for an 
adequate evaluation  of the primary efficacy parameter ( i.e., the ACR20 response rate at 
EOT ). Considering  other parameters of upmost significance for the evaluation of 
JTE-051’s efficacy , such as ACR50 and ACR70, an hs -CRP cut -off above 1.[ADDRESS_1066916], to ensure a comparable distribution of high vs. lower hs -CRP subjects across 
treatment groups . Minimum of a 12-week stable dos ing ( with respect to dose and the 
route of administration ) for the background MTX and for the other non-biologic 
DMARDs permitted by [CONTACT_776820]-inflammatory and anti- pain medications (including corticosteroids and NSAIDs ), as 
well as other anti -RA m edications administration have been set, in order to ensure that 
the maximum efficacy response to these medications has been attained and that the 
subject is stable by  [CONTACT_776821] , and to subsequently 
27 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066917] s at high risk of developi[INVESTIGATOR_443855]- related AEs, 
such as infections or malignancies , including those with pre -existing conditions  (e.g., 
clinically -manifest or latent tuberculosis,  active infections with hepatitis B or C viruses  or 
the human immunodeficiency virus [HIV] infection)  or significant hematological 
abnormalities  (see Exclusion Criterion # 3)  are excluded from participating in the study. 
 
 
 
 
 Other , general safety -related restrictions , such as cardiovascular -system -
related , hepatic and renal function- related  restrictions  have been implemented, taking int o 
account the co -administration with MTX  (a medication with known significant hepatic 
and renal -related toxicity ), as well as  the known safety signals associated  with other  
comparable compounds on the market or in development (e.g., hepatic or lipid- related 
signals) . The procedures set in place to ensure that the appropriate subjects are 
randomized in this “first -in patient” POC study in subjects with RA , as well as the safety 
management strategies implemented in the study are discussed in the following section : 
“Justification for Study Design”.   
Justification for Study Design 
A parallel group, placebo-controlled, add-on therapy design will be employed in this 
study, to assess the effect of JTE -051 on the efficacy parameters  and to evaluate the safety 
of JTE-051, compared to placebo  in subjects with active RA . Briefly, upon completion of 
all protocol -mandated  screening procedures , the qualified subjects  will be randomized at 
Visit 2 in a 1:1:1:1:1  ratio to one of the following five parallel dose groups: JTE -051 
50 mg QD, JTE -051 100 mg QD, JTE -051 150 mg QD, JTE -051 200 mg QD  or placebo 
QD ([ADDRESS_1066918] s to be randomized per arm ; see Section [IP_ADDRESS] for considerations related 
to sample size calculation ), and will receive the double -blind (DB)  treatment for 
12 weeks  followed by a four- week Follow -up Period. The single -dose AE051-U-11-001 
28 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066919] on the PK of JTE -051; thus, study drug  will be 
administered regardless of meals ; nonetheless, the protocol requires that the  once daily  
study drug administration to occur in the morning , to ensure an approximately 24-hour 
period between dosing, based on the PK characteristics of the compound (see 
Section  1.2.2) . The duration of the DB  Treatment  Period is sufficient to allow  for proof of 
efficacy  in subjects with RA , as an initial step in development . Following attainment of 
this objective, longer -duration (≥6 months) studies, including open- label ex tensio ns, as 
appropriate, are planned. The duration of the Follow -up Period was set to approximately 
four weeks, standard duration for similar out- patient studies administered an 
investigational product. C onsidering the PK characteristics of JTE -051 (see Section  1.2.1), 
it was determined that this  interval is conservative,  
a  
The efficacy parameters assessed  in this study are consistent with the standards in the 
industry in similar RA trials   
 Appropriate efficacy analyses are 
planned, as detailed in Section  [IP_ADDRESS]. To minimize the chance for errors, all calculations 
of derived parameters will be done by [CONTACT_776822]. Additionally, although all joint 
evaluators  in the study are expected to be rheumatologists  with experience in joint 
assessments, adequate training on these assessments is planned, to ensure consistency and to minimize intra - and inter -assessor variability. For this reason, the protocol also 
strongly recommend s that the same assessor perform s the joint counts for a subject 
throughout the study duration. 
With respect to safety, adequate procedures have been i mplemented to minimize the risks 
to the study subjects  (based on the compound’s MOA and the nonclinical and clinical 
data available to date [see Sections 1.2.1 
 f
or summary information and the 
Investigator’s Brochure for detailed information] ) and to facilitate further characterization 
of the safety profile of JTE -051.  
Specifically ,  
  
 screening procedures were set in place to exclude 
subjects at high risk of infections (e.g., medical history, chest radiography and serologic 
screening for tuberculosis, screening for hepatitis B and C, as well as HIV infections) and adequate withdrawal criteria, based on the Common Terminology Criteria for Adverse 
Events  (CTCAE), see Section 3.4, have been implemented.  
 
29 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066920] 
to the musculoskeletal AE, c onsidering the underlying disease of subjects in 
this study  (i.e., RA) , it is expected th at musculoskeletal -related signs and symptoms will 
be common; thus , differentiation by [CONTACT_776823], 
i.e., underlying disease  vs. potential other causes will be required .  
 
 
 These type of events  will be adequately managed through the 
standard AE  collection, processing and reporting  procedures, per Good Clinical Practice 
(GCP ) and all act ions to ensure the safety of the subjects will be taken by [CONTACT_47203] . Additionally, the CTCAE withdrawal criteria will be applied to all AEs 
reported in the study.  
    
 The safety data obtained after the completion for the study will facilitate a better 
understanding of the compound’s safety profile as a steppi[INVESTIGATOR_776797].    
Justification for Dose Selection  
The selection of JTE -051 doses in this study is based on the collective data from 
nonclinical pharmacology/toxicology studies and Phase 1 clinical studies.  
  
 
30 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
     
 
 
 
    
31 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
2 S
TUDY OBJECTIVES  
• To evaluate the clinical efficacy of JTE -051 in subjects with active rheumatoid 
arthritis  receiving background non-biologic disease- modifying anti -rheumatic drug  
therapy  
• To evaluate the safety and tolerabil ity of JTE -051 administered for 12 weeks to 
subjects with active rheumatoid arthritis receiving background non-biologic 
disease-modifying anti-rheumatic drug therapy  
• To evaluate the pharmacokinetics of JTE -051 in plasma of subjects with active 
rheumatoid a rthritis   
3 INVESTIGATIONAL PLAN  
3.1. Number of Sites and Subjects  
Multiple sites will be employed to ensure screening of sufficient number of subjects to 
randomize (in a 1:1:1:1:1  ratio) approximately 250 subjects (50 subjects per treatment 
group).  
3.2. Study Design 
This is a multicenter, randomized, double -blind, placebo controlled, parallel -group, 
12-week study in biologic and kinase inhibitor treatment- naive RA subjects on stable 
background non-biologic DMARD therapy, including MTX. 
Eligible subjects will be random ized at Visit 2 to receive JTE -051 50 mg, 100 mg, 
150 mg , 200 mg  or placebo once daily for 12 weeks. Subjects  will continue to receive up 
to two  non- biologic DMARDs, including MTX throughout the study (at a stable 
background dose and route of administration for at least 12 weeks prior to Visit 2 and 
throughout the study)  and will return for a Follow -up Visit approximately four weeks 
after the last dose of study drug is administered . Randomization will be stratified by 
[CONTACT_776824] g hs- CRP . 
The study duration will be of a pproximately [ADDRESS_1066921]:  
• Up to a 28- day Screening P eriod  
Note : Certain pre- defined  exceptions  that would allow  for a longer duration of 
the Screening Period to ensure a 28- day pre -randomization stabilization of 
concomitant medication s are permitted, as described in Section  [IP_ADDRESS]. 
32 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
• A 12-week double- blind Treatment Period  
• Approximately a [ADDRESS_1066922]. 
3.3.1.  Inclusion Criteria  
1. Males and females, 18 to 75 years of age (inclusive) at the Screening Visit  (Visit 1) ; 
2. A diagnosis of RA  prior to the Screening Visit , based on the ACR/EULAR 2010 
Classification Criteria23 (see Appendix 1) ; 
3. Active disease despi[INVESTIGATOR_776798] [ADDRESS_1066923] s, 
including MTX at both the Screening and Baseline Visits  (Visit 1 and Visit 2) , as 
defined by [CONTACT_17588]: 
a. ≥6 out of 68 tender joints AND 
b. ≥6 out of 66 swollen joints;  
4. Screening hs -CRP ≥ 1.[ADDRESS_1066924], based on the central laboratory values ;  
5. Background treatment with up to [ADDRESS_1066925] s, including MTX  
(mandatory) and one of the following medications  (optional) : sulfasalazine ≤ 3 g/day , 
hydroxychloroquine ≤400 mg/day  or chloroquine: ≤250 mg/day , at the time of the 
Screening Visit  (Visit 1); 
• The MTX dose must be  15-25 mg/week  (or the maximum documented tolerated 
dose for the subject, not <10 mg/week) and all ba ckground therapy must be stable, 
defined as no change in dose  or route of administration for ≥ 12 weeks prior to the 
Randomization Visit (Day 1).  See Section  [IP_ADDRESS] for all concomitant 
medication -related restrictions. 
6. Body Mass Index (BMI): 18 to 40 kg/m2 (inclusive) at the Screening  Visit (Visit 1) ; 
7. Females may participate if they meet one of the following criteria:  
• Surgically sterile (e.g., hysterectomy or bilateral oophorectomy), or 
• Post- menopausal (i.e., his tory compatible  with menopause [i.e., reported lack of 
menses for ≥12 months prior to Visit 1] and no other biological/surgical cause 
AND a serum follicle -stimulating hormone ( FSH) measurement of ≥40  mIU/mL 
at Visit 1), or 
• Of childbearing potential and are compliant with  at least 2 acceptable forms of 
birth control (in conjunction with their partner) for the duration of the study and for at least [ADDRESS_1066926] dose of study drug . Acceptable contraceptive 
methods include the following: intrauterine devices; partner sterilization (with the 
33 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066927] -vasectomy documentation of the absence of sperm in the 
ejaculate); condom with a spermicide; diaphragm, cervical cap, vaginal sponge, or 
“female condom”, all with spermicide;  
Notes:   
• Females with sterilization history limited to tubal ligation will be considered of childbearing potential and must comply with the contraception regimen as described above. 
• Females with a history compatible with menopause and have a serum FSH <40 mIU/mL at Visit [ADDRESS_1066928] agree to comply with a contraceptive regimen as described above. 
• Concomitant use of a female condom and a male condom is not considered an acceptable method of contraception for the study. 
8. Males with female partners of chi ldbearing potential must agree to practice total 
abstinence or to utilize a barrier contraceptive method with spermicide for the duration of the study and for at least [ADDRESS_1066929] dose of study drug; 
additionally, male subjects must not donate sperm for the duration of the study and 
within [ADDRESS_1066930] dose of study drug; 
• Female p artners of male subjects randomized in this study must be surgically 
sterile, postmenopausal, or use an acceptable form of birth control (see description 
listed  in inclusion criterion # 7; additionally , oral and implantable hormonal 
contraceptives are considered acceptable in female partners of male subjects ) for 
the duration of the study and for at least 12 weeks after completing the study; 
9. Able and willing to give written informed consent. 
3.3.2.  Exclusion Criteria  
The following criteria will exclude a subject  from participating in the study:  
1. Prior/current  exposure to biologic and/or kinase inhibitor therapy;   
2. Does not meet  all study restrictions, including previous/concomitant medication 
restriction criteria, as described in Section 3.5.4 of the protocol; 
3. White blood cell count of <3.0 x 10
9/L (<3000/mm3), absolute neutrophil count 
of <1.5 x  109/L (<1500/mm3) or absolute lymphocyte count <0.8 x 109/L (<800/mm3) 
at the Screening Visit  (Visit 1) ; 
4. Hemoglobin <9 g/dL  or platelet count <100,000/mm3 at the Screening Visit  (Visit 1) ; 
5. Alanine aminotransferase ( ALT ) >1.[ADDRESS_1066931]; aspartate aminotransferase 
(AST ) >1.[ADDRESS_1066932] or t otal bilirubin >1.[ADDRESS_1066933] at the Screening Visit  
(Visit 1) ; 
34 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
6. Clinical e vidence of renal impairment  or an estimated glomerular filtration rate 
(eGFR)  ≤60 mL/min /1.73m2 at the Screening Visit  (Visit 1) , using t he abbreviated 
Modification of Diet in Renal Disease (MDRD) equation ; 
7. Serum triglycerides >400 mg/dL at the Screening Visit (Visit 1) ; 
8. Positive viral serology at the Screening Visit (Visit 1) for: 
• Human immunodeficiency virus: positive HIV antibodies ( Ab)   
• Hepatitis B  virus : positive total hepatitis B core ( HBc)  Ab or positive hepatitis B 
surface antigen ( HBsAg ) or  
• Hepatitis C virus (HCV) : positive  HCV Ab ; 
9. Positive drug of abuse and alcohol test results at the Screening Visit (Visit 1) ; 
Note: Adequate (i. e., non- abusive) use of prescription drugs, according to the 
Investigator’s judgment is permitted, provided that the concomitant medications 
restrictions required by [CONTACT_776825]. Positive test results for cannabinoids will result in exclusion of subject from the study. 
10. History or presence of substance abuse, drug addiction or alcoholism within 1 year 
prior to the Screening Visit (Visit 1) ; 
11. Positive Purified Protein Derivative  ([COMPANY_003]) or quantiFERON
®-TB Gold -In-Tube test 
(Note: either test can be perf ormed, according to the local guidelines), positive chest 
radiography findings for tuberculosis or any other evidence of tuberculosis; 
• For subjects with a history of Bacille Calmette -Guérin (BCG) vaccination the 
quantiFERON®-TB Gold -In-Tube test should be performed;  
• A [COMPANY_003] test is considered positive if, at 48 to 72 hours of administration, the 
induration (not erythema) obtained is ≥5 mm .  
• If the quantiFERON®-TB Gold -In-Tube test is performed and it is indeterminate, 
a retest is allowed if results can be obtained in time prior to Visit [ADDRESS_1066934] may be performed  (unless the subject 
has a history of BCG vaccination) and, if negative, the subject may be randomized 
into the study. 
• The quantiFERON®-TB Gold -In-Tube test should not be performed within 
≤4 weeks from the date of a live vaccination .  
• Subjects  who have had contact [CONTACT_4490] a person with active tuberculosis are excluded, 
unless documentation of appropriate completion  (>12  weeks prior to the 
Screening  Visit)  of tuberculosis prophylaxis is provided to the investigator. 
12. History of live attenuated vaccination within 6 week s prior to Day 1 (Visit 2) , or have 
a live attenuated vaccination planned during the course of the study or within [ADDRESS_1066935] dose of study drug; 
35 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066936] donated or received any  blood or blood products within 8 weeks prior to the 
Screening Visit (Visit 1) ; 
14. History of a clinically -significant infection (e.g., required oral antimicrobial or 
antiviral therapy) within 8 weeks prior to Day 1 (Visit 2) , except for treated urinary 
tract infections, which will be permitted if resolved > 1 week prior to Day 1 (Visit 2) ; 
Note: Subjects  with confirmed Zika infection within 4 weeks prior to the 
Screening  Visit (Visit 1)  are prohibited to participate in the study, whether or not 
they have received  antiviral therapy.  
15. History of opportunistic infections or infection requiring hospi[INVESTIGATOR_776799], antiviral, antifungal, or antiparasitic therapy within 6 months prior to Day 1 
(Visit 2)  or any history of recurrent infections or conditions predisposing to chronic 
infections (e.g., bronchiectasis, chronic osteomyelitis) ; 
16. History of shingles  within 12 months prior to the Screening Visit  or any known 
history of disseminated/complicated herpes zoster ; 
17. History of acute inflammatory joint disease o f an origin other than RA or subject has 
any other rheumatic disease other than RA (e.g., any arthritis with onset prior to age 16 years , gout, mixed connective tissue disease, seronegative spondylarthropathy, 
psoriatic arthritis, reactive arthritis  or systemic lupus erythematosus)  or fibromyalgia ;  
Note:  Subjects with Sjögren's syndrome secondary to RA are permitted in the study  
provided that all other inclusion/exclusion criteria are met;  
18. History or presence of any lymphoproliferative disorder, such as Epstein Barr 
Virus -related lymphoproliferative disorder, lymphoma, leukemia, multiple myeloma , 
etc., or signs and symptoms suggestive of current lymphatic disease, such as 
Hodgkin's or Non -Hodgkin's lymphoma;  
19. History of or current malignancies with the exception of  adequately treated or excised 
non-metastatic basal cell or squamous cell  carcinoma of the skin or cervical 
carcinoma in situ > 6 months prior to the Screening Visit (Visit 1) ; 
20. History of organ transplantation; 
21. Acute coronary syndrome (e.g., myocardial infarction or unstable angina), percutaneous coronary intervention ( Percutaneous Transluminal Coronary 
Angioplasty [PTCA]  or similar procedures), coronary artery by[CONTACT_9292] (CABG) 
surgery, cerebrovascular accident or transient ischemic attack  (TIA)  within 6 months 
prior to the Screening Visit (Visit 1 ); 
22. Any history or presence of C lass III or IV heart failure, as defined by [CONTACT_380767]  (NYHA)
[ADDRESS_1066937] category 4 or higher  peripheral 
arterial  disease;  
23. Any history or presence of clinicall y significant arrhythmias or other ECG 
abnormalities, according to the Investigator’s judgment; 
36 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
24. Uncontrolled arterial hypertension defined a s repeated (i.e., up to 3 repeat 
measurements are allowed) systolic blood pressure ≥160 mmHg or diastolic blood 
pressure ≥100 mmHg  at the Screening Visit  (Visit 1); 
37 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
32. Pregnant or nursing females  at Screening Visit or Day 1  (Visit 1 and Visit 2)  or 
subjects who plan to become pregnant or init iate breastfeeding during the study a nd 
within [ADDRESS_1066938] dose of study drug;  
33. Significant history of drug or other hypersensitivities ( e.g., multiple drug allergies or 
severe allergic reactions, including angioedema);  
34. History or presence of any other clinically relevant medical condition or disease, or 
laboratory abnormality, including hepatic, renal, gastroenterologic, respi[INVESTIGATOR_696], 
cardiovascular, endocrinologic,  psychiatric  
(e.g., schizophrenia, manic -depressive disorder , treatment -resistant major depression), 
immunologic (e.g., immunocompromised subjects or subjects with autoimmune 
conditions other than RA , such as type I diabetes ) or hematologic  (e.g., sickle cell)  
disease that, in the opi[INVESTIGATOR_689], may place the subject  at unacceptab le 
risk for study participation and may prevent the subject from completing the study  
(e.g., low life expectancy, high risk of non- compliance) or would interfere with the 
study conduct or data interpretation, according to the Investigator’s judgment; 
35. Cannot communicate reliably with the Investigator (including inability to complete the self -assessment questionnaires) or are unlikely to cooperate with the requirements 
of the study.   
38 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066939] will not participate  further in the study under the following conditions: 
1. Withdrawal by [CONTACT_27720] : subjects  have the right to withdraw from the study at any 
time. However, if a subject withdraws consent because of experiencing an adverse 
event, the reason for subject termination should be documented as the adverse event . 
2. Adverse Event : a clinical or biological adverse event or intercurrent condition(s), 
requiring study drug discontinuation, whether or not related to the study drug 
If grade 3 findings (defined as severe or medically signi ficant but  not immediately 
life-threatening;  hospi[INVESTIGATOR_185854]; 
disabling; limiting self -care activities of daily living [ADL] such as bathing, dressing, 
undressing, feeding self, using the toilet, taking medication, but not bedridden), 
according to the CTCAE25, are noted in a subject, he/she must be promptly evaluated 
by [CONTACT_737] (including repeat tests, evaluation of the baseline parameters, concomitant medicat ions, etc.) for potential withdrawal from the study. Every effort 
should be made to discuss with the study’s Medical Monitor prior to final decision, unless not feasible, based on safety considerations . Subjects who interrupted study 
drug administration  due to a g rade 3 CTCAE finding may be re -started on therapy if 
the event has resolved  and it is considered appropriate by [CONTACT_776826]. 
Note s:  
• The investigator may decide to evaluate or withdraw the subject from the study based o n findings of lesser than grade 3 severity, according to his/her judgment. 
 
3. Consistent* N on-compliance with Study Drug  (i.e., <80% or >120% compliance ; 
exceptions  on a case-by- case basis  may be permitted if approved by [CONTACT_604497]) 
*Determined at >1 study visit during the Treatment Period . If compliance of 
<80% or >120% is identified at a study visit, the Investigator or designee is to 
counsel the subject and ensure steps are taken to improve compliance. 
39 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
4. Inclusion/Exclusion Criteria Not Met: the subject was randomized in the study and 
did not meet all inclusion/exclusion criteria mandated by [CONTACT_760] (exceptions  on 
a case-by- case basis may be per mitted if approved by [CONTACT_35886])  
5. Protocol Violation : the subject is non- compliant with regard to this protocol (other 
than the withdrawal criteria  3. and 4. listed above ), as determined by [CONTACT_776827] 
6. Lost to Follow-up 
7. Death  
8. Study Terminated by [CONTACT_2728] : the sponsor may suspend or terminate the study or 
part of the study at any time for any reason 
9. Pregnancy  
10. Investigator Decision : the Investigator decides a subject should be discontinued for 
any reasons other than those already mentioned ( actual reason must be documented 
by [CONTACT_3725] ) 
11. Other : actual reason must be documented by [CONTACT_776828] [ADDRESS_1066940] will undergo all the procedures 
described for Visit 6 (EOT) . Every effort should be made to perform the EOT 
asses sments as soon as possible after the decision of discontinuation is made and prior to 
any changes made in the subject’s anti -RA therapy. Additionally, at approximately 
[ADDRESS_1066941] should return for a Follow -up V isit, 
where all procedures as described at Visit 7 should be performed.   
  
  
40 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.5. Study Procedures  
Figure 1. Planned Study Schem a 
 
 
 
           
 
 
41 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Table 1. Planned Schedule of Study Procedures  
  
Screening
PeriodFollow -up
Period
Duration/ Study Week (Day)a Up to 4 
weeksWeek 0
(Day 1)Week 2
(Day 14±2)Week 4
(Day 28±2)Week 8
(Day 56±2)Week 12
(Day 84±2)Week 16
(Day 112±2)
Visit 1 2 3 4 5 6 7
Informed Consent X
Inclusion/ Exclusion Criteria X X
Medical History X
Demographic Information X
Review Prior/ Concomitant Medications X X X X X X X
Physical Exam X X X X X X
Vital Signs, including Weight X X X X X X X
Height and Calculate BMI X
12-Lead ECG X X X X
Chest RadiographycX
TB test ([COMPANY_003] or quantiFERON gold) X
Drugs of Abuse Screen X
Viral Serology X
FSH (post-menopausal females only) X
Pregnancy Test (all females)dX X X X X X X
Serum Biochemistry X X X X X X X
Hematology X X X X X X X
Urinalysis X X X X X X X
Coagulation X X X X X
Lipid Profile X X X X X
25-hydroxyvitamin D X
Serum IgG, IgM and IgA X X
RFe and Anti-CCP antibodiesf X
Bone-specific ALP X X X
hs-CRP X X X X X X X
CRP X X
Tender Joint Count (68) X X X X X X X
Swollen Joint Count (66) X X X X X X X
Subject's Assessment of Arthritis Pain X X X X X X X
Subject's Global Assessment of Arthritis X X X X X X X
Physician's Global Assessment of Arthritis X X X X X X X
HAQ-DI X X X X X X X
Randomization using IWRS X
Access IWRS and Dispense Study DruggX X X X
Collect Study Drug and Check CompliancehX X X X
Study Drug AdministrationiX X X X
JTE-051 Trough PK Blood Samples X X X X
Document Adverse EventsjX X X X X X XTreatment  Period
 
a. The target day for each  visit timepoint will be calculated relative to the date of 
Randomization Visit (Visit 2) and not relative to the date of the previous visit. A ll visits 
should be performed within the windows specified in the table. Every attempt should be 
made to have the  subject attend each visit as scheduled. The investigational site is 
encouraged to a make a reminder phone call to the subject approximately a day or two before the scheduled visit. However, if a subject is unable to attend a visit within the specified 
42 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066942] radiography had been performed within 3 months (12 weeks) of the 
Screening  Visit, and documentation is available for review by [CONTACT_776829]’s file.  
d. At Visit [ADDRESS_1066943]  will be performed; at all other visits, urine pregnancy tests 
will be performed. Pregnancy tests may also be repeated as needed or per request from 
IRBs/IECs or if required by [CONTACT_427]. 
e. Rheumatoid F actor  
f. Anti-cyclic citrullinated p eptide antibodies  
g. At Visit 2, a back -up drug blister card will be dispensed to all subjects, in addition to the 
regular study drug blister cards. Subjects will be instructed not to use the back-up blister card  
unless all dr ug in the regular blister card s has been used and to bring all used and unused 
(including back -up) blister card s to each study visit for accountability purposes. At Visit 6, 
study drug will not be dispensed. If a study subject discontinues study drug prematurely, the 
appropriate systems will be accessed to record termination as soon as possible after the 
decision has been made.  
h. Study drug compliance will be calculated by [CONTACT_776830] 3, based on the number of tablets dispensed /returned by [CONTACT_423]. 
The subject is to maintain the back -up blister card for the duration of the Treatment Period. 
i. Oral administration for 12 weeks starting on the day of randomizat ion at Visit 2, QD in the 
morning, regardless of meals. On study visit days, subjects should take their scheduled study 
treatment from their existing study drug supply (if available) at the site , under the 
supervision of the investigator or designee after all study -related procedures have been 
perfor med (except for Visit 6, whe n no study drug will be administered, as the last dose will 
be taken the day prior to the visit). If no tablets from the previously  supplied non- back -up 
blister cards are av ailable, then the subject should dose from the new blister card  supplied at 
that visit.  Following completion of accountability and compliance assessments, the back -up 
blister card will be re -dispensed at Visits [ADDRESS_1066944] should only be utilized by 
[CONTACT_776831] -supplied (i.e., non- back -up) blister cards has 
been used. 
j. Adverse event information will be collected at the sp ecified time points as well as at any 
time when a clinical research unit staff member becomes aware of an AE after the subject signs the informed consent for the study. However, stable or improving pre -existing 
conditions that are detected through the screening procedures throughout the Screening  Period  (e.g., abnormalities in ECG, physical examination,  
 vital signs, and laboratory tests) are consid ered to be medical history and 
should be documented accordingly. 
43 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.5.1.  Screening Period 
Day -28 (Visit 1) to Day 1 (Visit 2) 
Following signature [CONTACT_776883], screening procedures to 
confirm eligibility may be performed across multiple days, as needed, during the Screening Period. If a subject arrives for a visit not having fasted (overnight fast, at least 
10 hours prior to blood and urine sample collection), all study procedures with the 
exception of the blood/urine collection activities may be performed; the subject’s remaining procedures  will be rescheduled for blood/urine collection on a subsequent day 
within the visit w indow and he/she will be reminded to fast overnight.  
Please refer to Table [ADDRESS_1066945] of s creening  procedures to be performed in the study. A 
one-time repeat of the screening laboratory  (except for drug s of ab use and alcohol, viral 
serology and pregnancy tests ), vital sign and ECG assessments is permitted, if considered 
appropriate by [CONTACT_737], except if stated otherwise  (e.g., an up to a three -time 
repeat of blood pressure measurements at  the Screening  Visit is permitted). The repeat 
test(s) results are to be utilized for subject qualification purposes. If the repeat test results 
are outside the protocol-required range, the subject should be excluded from the study.  
Re-screening of subjects may be perm itted on a case-by- case basis, pending discussion 
and approval by [CONTACT_7195]. 
3.5.2.  Double- blind Treatment Period 
Day 1 (Visit 2) to Day 84 ±2 (Visit 6/Week 12) 
Please refer to  Table [ADDRESS_1066946] of p rocedures to be performed in the study 
during this period.  
All visits during the Double-blind Treatment Period (i.e., including Visit 2 
[Randomization Visit]), should be performed under fasted conditions (overnight fast, at 
least 10 hours prior to blood and urine sample collection). If a subject arrives for a visit 
not fasted, then all study procedures with the exception of the blood/urine collection activities may be performed; the subject’s remaining procedures  will be rescheduled for 
blood/urine collection on a subsequent day within the visit window and he/she will be reminded to fast overnight. Exception to this would be Visit 2 (Randomization Visit), at which all study procedures have to be completed within the same session, therefore,  if the 
subject i s not fasted, the full visit should be rescheduled. 
All visits should be performed within the windows specified in the table. Every attempt should be made to have the subject attend each visit as scheduled. The investigational site is encouraged to a make a reminder phone call to the subject approximately a day or two before the scheduled visit. However, if a subject is unable to attend a visit within the specified windows, the visit should be scheduled as closely as possible to these windows. A subject should not skip a protocol- specified visit due to scheduling difficulties . 
44 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066947] dose of study drug in the clinical research center, 
upon completion of all pre -dosing procedures and randomization at Visit 2; subsequently, 
they will be instructed to self -administer study drug once daily , in the morning , regardless 
of food. However, subjects should not take study drug in the morning of the day of a 
study visit until after all  study procedures have been completed. On those days study drug 
will be administered at the site  by [CONTACT_776832]’s previously 
supplied non- back -up study drug blister cards , if available , except for Visit 6, when no 
study drug will be administered, as the last dose will be taken the day  prior to the visit . If 
no tablets from the previously  supplied non- back -up blister cards are available, then the 
subject should dose from the  new non-back -up blister card supplied at that visit. 
Following completion of accountabi lity and compliance assess ments, t he back -up blister 
card will be re- dispensed at Visits [ADDRESS_1066948] should only be utilized by [CONTACT_776833] -supplied (i.e., non- back -up) blister cards has been 
used. If the subject inadvertently took study drug on the day of the study visit, prior to the 
visit, he/she may complete the visit and the actual date and time of the last dose prior to 
the PK blood samples coll ection will be  accurately recorded.  
The exact date and time of last dose prior to the PK sample collection at each visit should be documented.  
Study drug will not be administered and all drug will be collected from the subjects at 
Visit 6.  If a subject d iscontinues the study prematurely after receiving at least one dose of study 
drug, an Early Termination Visit should be completed at which all procedures listed for 
the EOT visit (Visit 6) should be performed, if possible, prior to initiation of any change 
in the anti -RA medication  regimen of the subject . 
3.5.3.  Follow -up Period 
Day 84 ±2 (Visit 6/Week 12) to Day  112 ±2 (Visit 7/Week 16)  
The Follow-up V isit will occur approximately four weeks after the last dose of study drug. 
Similar to all other study visits,  subjects should arrive under fasted conditions 
(i.e., overnight fast, at least 10 hours prior to blood and urine sample collection). Please refer to Table [ADDRESS_1066949] dose of study drug. 
45 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.5.4.  Study Restrictions  
[IP_ADDRESS].  Previous and Concomitant Medication Restrictions  
Medications PROHIBITED  any time prior or during the study  (through the Follow -
up Visit [Visit 7]): 
• Biologic s and kinase inhibitor agents; 
• Antipsychotic therapy; 
• Anti- retroviral therapy  and alpha- interferon ;  
• Anti- cancer chemotherapy ; 
Note : Methotrexate, as background treatment for RA is permitted; 
• Tacrolimus  and mycophenolic acid/mycophenolate mofeti (MMF)   
Medications PROHIBITED within  6 months (24 weeks)  prior to Day 1 (Visit  2) 
through the F ollow -up V isit (Visit 7 ): 
• Cyclophosphamide. 
Medications PROHIBITED within 3 months (12 weeks) prior to Day 1 (Visit  2) 
through the Follow -up  Visit ( Visit 7 ): 
• Oral or injectable gold, azathioprine, penicillamine and cyclosporine; 
• Leflunomide, unless the subject  has under gone cholestyramine washout at least 
28 days prior to Visit 2;   
• Monoamine oxidase inhibitors; 
• Isoniazid. 
Medications PERMITTED AT STABLE DOSE for at least 3 months (12 weeks) 
prior to Day 1 (Visit 2) through the Follow -up  Visit ( Visit 7 ): 
• All subjects mus t receive background MTX at stable doses of 15-25 mg/week , or at the 
maximum documented tolerated dose for the subject, not <10 mg/week. For the 
purpose of the study “stable” is defined as no change in dose  or route of MTX 
administration  for ≥[ADDRESS_1066950] not change throughout the study (i.e., until after the 
Follow-up Visit [Visit 7]); 
 Supplementation with folic acid or folinic acid  (leucovorin) , according to the local 
stand ard of care (SOC) (i.e., local MTX package insert) is required in all subjects  
as follows : subjects must receive folic acid between [ADDRESS_1066951] 7 mg total weekly dose, unless 
this regimen viola tes the local MTX label, case when the later should be followed. 
Alternatively, study subjects may receiv e folinic acid (leucovorin) up to 5 mg per 
dose administered 8 to 24 hours after the MTX weekly dose. Dosing regimen for 
folic acid/folinic acid must b e stable for at least 4 weeks (28 days) prior to Visit 2. 
46 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Note : If the subject  has not been receiving folic acid or folinic acid prior to signing 
the informed consent, then a prescription for dosing according to the local SOC  
and MTX package insert must be  provided by [CONTACT_776834] . In this case, the duration of Screening  Period  may 
be extended by [CONTACT_307133], to allow for a 4- week ( 28-day) stabilization  period for 
folic acid/folinic acid .  
• Sulfasalazine ≤ 3 g/day , hydroxychloroquine ≤400 mg/day  and c hloroquine: 
≤250 mg/day ; 
Note:   
 If a subject  has not been on stable treatment with these drugs  for at least [ADDRESS_1066952] not be initiated  until after the Follow -up Visit (Visit 7); 
 For candidates receiving chloroquine or hydroxychloroquine, fundoscopic and 
visual field examination results performed within the timeframe consistent with the local SOC, but not exceeding  [ADDRESS_1066953]’s source documents. If not 
available, such examinations should be performed (as part of SOC) and results should be reviewed/filed by  [CONTACT_776835] r to randomization; 
• Selective serotonin reuptake inhibitors (SSRIs), serotonin- norepi[INVESTIGATOR_59446] (SN RIs), bupropi[INVESTIGATOR_2394] (Wellbutrin) and tricyclic or tetracyclic antidepressants . 
Medications PROHIBITED within 4 weeks  (28 days)  prior to Day 1 ( Visit  2) 
through the Follow -up  Visit (Visit 7): 
• Parenteral or intra- articular corticosteroids , as well as oral prednisone/prednisolone or 
steroid equivalent at doses >10 mg/day; 
Note : Topi[INVESTIGATOR_776800] 
• Doxycycline and minocycline;  
• Pentoxifylline ; 
• Sulfamethoxazole/Trimethoprim (Bactrim) , sulfones (e.g., Dapsone), colchicine and 
systemic metronidazole; 
• Vitamin B 6 at doses >100 mg/day ; 
• Cannabinoids, including marijuana. 
Medications PROHIBITED within 4 weeks  (28 days)  PRIOR TO VISIT 1  
(SCREENING VISIT)  through the Follow -up  Visit (Visit 7): 
• Investigational drugs : prohibited within 4 weeks  or 5 PK  half-lives  prior to the 
Screening Visit  (Visit 1), whichever is longer;  
47 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 Subjects cannot participate in any other investigational or long- term observational 
studies related to an investigational medication after signing the AE051-G-13-003 
consent form  through the Follow- up Visit (Visit 7);  
Note:  Participation in registries and lon g-term population- based studies (e.g., nurse 
health studies) is permitted.   
 If the investigational drug was a biologic or a kinase inhibitor, the subject cannot 
be randomized in the study regardless of the timing of exposure. 
Medications PERMITTED AT STABLE DOSE  for at least 4 weeks  (28 days)  prior 
to Day 1 (Visit 2) through the Follow -up Visi t (Visit 7): 
• Oral prednisone/prednisolone or steroid equivalent at doses ≤ 10 mg/ day; 
• Daily doses of oral NSAIDs, cyclooxygenase (COX) -2 inhibitors, opi[INVESTIGATOR_776801]/paracetamol; 
 Subjects with occasional use (i.e., not  more than two consecutive days) of the 
above medications for indications other than RA (e.g., headache) may be permitted 
in the study pending discussion with the Medical Monitor, provided that the  intake 
of such drugs did not occur  within 1 week (i.e., 7 days) of Visit 2 and all other 
inclusion/exclusion criteria are met.  
• Hormone replacement, lipid-lowering, antihypertensive and anti-osteoporosis agents; 
 Following receipt of s creening lipoprotein a ssessment results, the investigator may 
initiate lipid lowering drug therapy, as appropriate, according to the local SOC and 
his/her judgment; such action should be taken as soon as possible, but not >2 business days from the time of receipt of the results  and in these cases the 
Screening Period may be extended with  the number of days necessary to meet the 
4-week ( 28-day) prior to Visit 2 stability requirement . 
• Over -the- counter, herbal, traditional, ayurvedic therapy, including vitamins, minerals 
and supple ments.  
• Vitamin D supplementation at doses according to the local standard of care is to be initiated in patients with Vitamin D concentrations below the  lower limit of normal at 
the Screening V isit. Dosing must be initiated immediately after the deficiency  is 
identified and should be stable for at least 4 weeks prior to JTE -051 dosing initiation 
and throughout the study (in this situation, the duration of Screening Period may be extended beyond 28 days to ensure a duration of Vitamin D stability of 28 days). 
• Generally, every effort should be made to ensure that all other permitted 
chronically -administered concomitant medications are taken by [CONTACT_776836]/route of administration for at least 4 weeks (28 days ) prior to Day 1, unless a 
change in dose/route of administration  is considered medically necessary.  
 
48 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
General M edication -related  Protocol I nstructions : 
 
•
 Generally, medication dose/route of administration changes or initiation of new 
medications during the conduct of the study is not recommended unless such actions are considered medically necessary, case when any appropriate action, according to 
the Investigator’s judgment should be taken; 
• All medications taken by [CONTACT_423] , including over -the- counter, herbal, traditional, 
ayurvedic compounds  (whether permitted or e xcluded by [CONTACT_760]) must be 
documented in the case report form ( CRF ); 
• Contact [CONTACT_776837]/concomitant therapy.  
[IP_ADDRESS].  General Restrictions  
• Joints that have been  injected with  corticosteroid medications within <6 weeks  of the 
assessment , were replaced or  are fused will not be included in the assessments. 
• Following enrollment in the study, subjects should continue all non- pharmacological 
therapi[INVESTIGATOR_014], such as physical therapy, as indicated and deemed appropriate for his/her physical condition. 
• Routine household contact [CONTACT_776838] (e.g., varicella, or attenuated typhoid fever, oral polio, attenuated rotavirus or inhaled flu vaccines) should be avoided during the study and for [ADDRESS_1066954] dose of study drug. 
• Travel to countries with known high prevalence of tuberculosis should be avoided from the time of signing the Informed Consent through the Follow- up Visit.  
• Local standard reco mmendations (e.g., insect repellents ) should be followed to 
minimize the risk of infection with the Zika virus  in subjects enrolled in the study. 
49 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
50 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
 
51 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.5.6.  Procedure Definitions  
[IP_ADDRESS].  Efficacy Assessments 
[IP_ADDRESS].1.  Quantitative  Joint  Assessments (68/66)  
Standardized 68 and 66 joint counts will be performed for assessment of the number of 
tender  and swollen joints, respectively, according to the schedule summarized in Table 1. 
See Figure 3 for a diagram of joints to be assessed as part of the 68/66 tender and swol len 
joint counts. Every effort should be made  to ensure that  the quantitative joint assessments 
is performed by a n experienced, trained independent assessor , different from the Principal 
Investigator/Sub- investigator  who is performing overall evaluation of  the subject.  The 
independent assessor must have medical training (e.g., he/she may be  a medical doctor, 
physician assistant, nurse practitioner or registered nurse), must have performed RA joint assessments for clinical studies prior to the current study  and must have under gone the 
joint count training provided by [CONTACT_776839] , as applicable. The  same assessor 
should perform the counting for a specific subject throughout the study  (scheduling of 
study subjects should take into account the assessor’s a vailability). In exceptional 
circumstances, if conditions do not permit the availability of the same assessor, an alternate assessor may perform the quantitative joint assessment provided that he/she meets that experience/training requirements as described  above . These exceptions should 
be documented and communicated to the medical monitor. Additionally, every effort will 
be made to limit the number of assessors within a site (ideally, the same assessor will perform the quantitative joint assessments for all subjects at a site). See Section [IP_ADDRESS] for the restrictions pertaining to the joints to be included in these assessments.  
Figure 3. Tender and Swollen Joint Counts (68/66) 
 
52 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
[IP_ADDRESS].1.1   Tender/Painful  Joint  Counts  (68) 
Sixty -eight (68) joints will be assessed to determine the number of joints that are 
considered tender or painful. A rtificial/ missing /fused  joints  or joints that have received 
corticosteroid injection within [ADDRESS_1066955] not be included in the 
assessment .  
The 68 joints to be assessed are: 
• Upper Body : temporomandibular (2), sternoclavicular  (2), acromioclavicular  (2); 
• Upper Extremity : shoulder (2), elbow  (2), wrist (2) (includes radiocarpal, carpal 
and carpometacarpal considered as one unit), metacarpophalangeals (MCP  I[2], II[2], 
III[2] , IV[2], V[2] ), thumb interphalangeal (IP)  (2), proximal interphalangeals (PIP 
II[2], III[2] , IV[2], V[2] ), distal interphalangeals (DIP II [2], III[2] , IV[2], V[2] ); 
• Lower Extremity : hip (2), knee(2), ankle(2), tarsus (includes subtalar, transverse 
tarsal and  tarsometatarsal considered as one unit)  (2), metatarsophalangeals (MTP 
I[2], II[2] , III[2] , IV[2], V[2]), great toe IP  (2), proximal and dis tal interphalangeals 
combined (PIP II[2] , III[2] , IV[2], V[2] ). 
[IP_ADDRESS].1.2   Swollen  Joint  Counts  (66) 
The joint assessor will also assess joints for swelling . Artificial/missing/fused joints or 
joints that have received corticosteroid injection within [ADDRESS_1066956] 
not be included in the assessment. 
The sixty -six (66) joints that will be assessed for swelling are the same as those listed 
above for tenderness/pain, except that the right and left hip joints are not included in the 
swollen jo int count.  
[IP_ADDRESS].2.  Quantitative  Joint  Assessments (28) 
The 28 joints utilized  for the calculation of certain efficacy parameters, such as Disease 
Activity Score ( DAS )28, Clinical Disease Activity Index (CDAI ) and Simplified Disease 
Activity Index  (SDAI ), see Appendix 5, are a sub -set of the 68/66 joints assessed per the 
instructions in Section  [IP_ADDRESS].1 (see Figure 4); thus, the results of the above -described 
68/66 joint assessments applicable to the 28 joints should be utilized when reporting the 
28-joint assessment results (i.e., no re- assessment of the 28 joints will be done ). 
53 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Figure 4. Tender and Swollen Joint Counts (28) 
 
[IP_ADDRESS].2.1.  Tender/Painful  Joint  Counts  (28) 
The twenty -eight tender/painful joint count includes the following joints: shoulders (2), 
elbows (2), wrists (2), MCP joints (10), PIP joints (10) and knees (2).  
[IP_ADDRESS].2.2.  Swollen  Joint  Counts  (28) 
The twenty -eight swolle n joint count includes the same joints as those included in the 
tender joint counts. 
[IP_ADDRESS].3.  Subject’s  Assessment of Arthritis  Pain 
Subjects will assess the severity of their arthritis pain  according to the schedule 
summarized in Table 1 using a  numeric rating scale ( NRS ) with 0 representing “no pain” 
and 10 representing “ pain as bad as it can be”. See Appendix [ADDRESS_1066957] pain assessment . Whenever  available, the local language- validated 
tool will be utilized.  
[IP_ADDRESS].4.  Subject’s  Global  Assessment (SGA)  of Disease  Activity  
Using a  [ADDRESS_1066958]’s global assessment of disease activity  scale. Whenever available, the local 
language -validated tool will be utilized.  
[IP_ADDRESS].5.  Physician’s  Global  Assessment (PGA)  of Disease  Activity  
The Investigator will assess the subject’s overall arthritis activity according to the 
schedule summarized in Table [ADDRESS_1066959]’s disease signs, functional capacity and physical examination, and should 
be independent of the SGA of disease activity.  See Appendix 3 for a template in English 
of the PGA of disease activity scale. Whene ver available, the local language- validated 
tool will be utilized.  
54 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
[IP_ADDRESS].6.  Health  Assessment Questionnaire Disability  Index  (HAQ -DI) 
The HAQ- DI assesses the extent of the subject ’s functional ability  by [CONTACT_776840] a subject has experienced during the past week in eight categories of daily 
living activities: dressing and grooming, arising, eating, walking,  hygiene, reach, grip, 
and common daily  activities.  Each category has at least two sub -category questions.  The 
subjects  report the amount of difficulty they have in performing some of these activities.  
The HAQ- DI is designed to assess the subject’s usual ability during the past week, not a 
particularly good or bad day. This questionnaire should be completed by [CONTACT_776841], if possible. The form should then be 
checked by [CONTACT_776842].  See Appendix [ADDRESS_1066960] University 
School of Medicine, Division of Immunology & Rheumatology  Health Assessment 
Questionnaire Worksheet and for instructions on handling the responses by [CONTACT_3786] , as well as  the scoring process that will be performed by [CONTACT_1034]. 
[IP_ADDRESS].7.  High-sensitivity  C-reactive Protein 
The blood samples for hs-CRP  measurements  will be collected according to the schedule 
summarized in Table 1 and will be analyzed by [CONTACT_2237].  
[IP_ADDRESS].8.  C- reactive Protein 
The blood samples for CRP measurements utilizing  the non- high sensitivity method will 
be collected at Visit 2 and Visit 6 and will be analyzed by [CONTACT_2237].  
[IP_ADDRESS].  Medical History  
A complete medical history will be obtained at the  Screening Visit  (Visit 1)  and will 
include evaluations for past or present conditions.   
 Stable or improving pre -existing conditions that are 
detected as part of the screening procedures  (e.g., E CG, physical examination, 
, vital signs, and laboratory test abnormalities ) are considered to 
be medical history.  
[IP_ADDRESS].  Prior/Concomitant Medications 
Information pertaining to all medication use (including prescription, over -the-counter, 
supplements, vitamins and minerals) will be collected for the period of at least 30 days 
prior to the Screening Visit (Visit 1) and throughout the study. For medications excluded for a longer than a 30- day period, as described in Section [IP_ADDRESS],  the timeframe for 
collecting this information will be extended to cover at least the exclusion period.  
With respect to the use of corticosteroids, detailed information (including but not limited 
to dose, route, indication, duration of administration)  will be obtained. E very effort 
should be made to document this informa tion from the time of first use by [CONTACT_423] , 
with focus on chronic use of these agents (i.e., having a duration of ≥  2 weeks); 
55 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
nonetheless, for the peri od within 30 days prior to Visit 1, all corticosteroid use 
(including short- term) will be documented.  
[IP_ADDRESS].  Physical Examination 
Physical examinations will be performed by a physician or qualified designee according 
to the schedule summarized in Table 1 and will include examination of the following 
body systems: general appearance, skin (including hair and nails), HEENT (head, ears, eyes, nose, throat), neck/thyroid, chest/lungs, cardiovascular, gastrointestinal, 
, psychiatric/emotional, lymphatic , and musculoskeletal.  
3.
5.6.6.  Height and Weight Measurem ents, and BMI Calculation 
Height and weight measurements will be performed according to the s chedule 
summarized  in Table 1. Subjects will remove their shoes and wear light clothing in order 
to be consistent between  measurements of height and weight. B ody mass index  will be 
calculated at the Screening  Visit (Visit 1)  using the following equation:  
(weight  (kg)  / height [m2]), where the weight in kilograms will be documented to one 
decimal place and the height in cent imeters will be rounded to the nearest whole number.  
[IP_ADDRESS].  Vital Sign s 
Vital sign assessments including blood pressure, pulse rate, respi[INVESTIGATOR_37499] ( °C) will be performed in a sitting position according to the sche dule 
summarized in  Table 1. Subjects must rest in a sitting position for at least 5 minutes in 
preparation for blood pressure and pulse rate assessments . 
[IP_ADDRESS].  12-Lead ECG   
Twelve- lead ECG recordings and conduction intervals including the i nterv al from 
beginning of the QRS complex in the frontal plane to the next QRS complex  (RR), the 
interval from beginning of the P wave to the beginning of the QRS complex in the frontal 
56 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066961] ( PR), duration of QRS complex in the frontal plane  (QRS ), interval fr om beginning 
of the QRS complex to end of the T wave in the frontal plane (QT), and 
Fridericia -corrected QT interval (QTcF) will be obtained according to the schedule 
summarized in  Table 1. Subjects will lay supi[INVESTIGATOR_221865] 5 minutes prior to the 12-lead 
ECG assessments.  
[IP_ADDRESS].  Hematology   
Blood samples to assess complete blood count including erythrocytes , hematocrit, 
hemoglobin, platelet s, leucocytes  and differential (percent and absolute [neutrophil, 
eosinophil, basophil, lymphocyte, monocyte])  will be obtained under fasted conditions 
according to the schedule summarized in Table 1. 
[IP_ADDRESS].  Serum Biochemistry  
Blood samples to assess serum ALT, albumin, alkaline  phosphatase (ALP), AST, 
bilirubin, BUN , calcium, carbon dioxide, chloride, creatine kinase, creatinine, 
gamma -glutamyl transferase, globulin, glucose, lactate dehydrogenase,  phosphate, 
potassium, protein, sodium and urate will be obtained according to the schedule  
summarized in Table 1. The eGFR will be calculated at each study visit by [CONTACT_776843]. [IP_ADDRESS].  Bone- specific Alkaline Phosphatase 
Blood samples to measure bone -specific alkaline phosphatase will be obtained  according 
to the schedule summarized in Table 1. [IP_ADDRESS].  Lipid Panel  
Blood samples to measure cholesterol,  low-density lipoprotein cholesterol  (LDL- C), 
high-density lipoprotein cholesterol ( HDL -C) and triglyceride s will be obtained according 
to the schedule summarized in Table 1. [IP_ADDRESS].  25-hydroxyvitamin D  
Blood samples to measure 25-hy droxyvitamin D will be obtained at the Screening Visit.  
[IP_ADDRESS].  Rheumatoid Factor, Anti -cyclic citrullin ated peptide antibodies, 
Serum Immunoglobulins G, M and A  
Blood samples to measure the r heumatoid f actor  (RF) , anti- cyclic citrullinated peptide 
(anti-CCP) antibodies and s erum immunoglobulins G, M and A  (IgG, IgM and IgA) will 
be obtained at the Screening  Visit.  
[IP_ADDRESS].  Coagulation 
Blood samples to assess prothrombin time  (PT) and activated partial thromboplastin time  
(aPTT)  will be obtained according to the schedule summarized in Table 1. International 
normalized ratio will also be calculated.  
57 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
[IP_ADDRESS].  Viral Serology  
Blood samples to assess H BsAg, HBc antibodies, HCV antibodies, and HIV antibodies  
will be obtained  at the Screening Visit  (Visit 1) . 
[IP_ADDRESS].  Pregnancy Test  
Pregnancy tests to assess βHCG levels will be performed for all female subjects. Blood 
samples will be collected at the Screening Visit (Visit 1 ) for a serum pregnancy test. At 
Visits [ADDRESS_1066962] from IRBs/IECs or if required by [CONTACT_13125]. 
[IP_ADDRESS].  Follicle -stimulating Hormone 
Blood samples to assess  the menopausal status will be collected at the Screening Visit 
(Visit 1) from all female subjects  who report a history compatible with menopause with 
no other identified biological/surgical cause.  [IP_ADDRESS].  Drugs of Abuse and Alcohol Screen  
Urine  samples to assess amphetamine, barbiturates, benzodiazepi[INVESTIGATOR_050], cannabinoids, 
cocaine, ethanol, opi[INVESTIGATOR_858], oxycodone and methadone will be obtained at the 
Screening  Visit (Visit 1)
.  
[IP_ADDRESS].  Tuberculosis Screening 
The Mantoux skin test (also known as the [COMPANY_003] test) or the Quantiferon®-TB 
Gold -In-Tube  test (according to the local SOC) may be used as tuberculosis screening 
tools for the study during the Screening Period.  
If the Mantoux test  is selected, the reaction must be read between 48 and 72 hours after 
administration (a subject that does not return after [ADDRESS_1066963]). The reaction will be measured in millimeters of the induration 
(palpable, raised, hardened area or swelling). The reader will not measure erythema 
(redness). The diameter of the indurated area will be measured across the forearm 
(perpendicular to the long axis). An indurat ion of 5 or more millimeters is considered 
positive. If the Quantiferon
®-TB Gold -In-Tube  test is performed, blood samples will be col lected, 
processed and shipped during the Screening Period, according to the laboratory 
instructions. In the case of an inde terminate Quantiferon®-TB Gold -In-Tube  test, the test 
may be repeated  up to one time if results can be obtained in time prior to Visit 2. If the 
retest is also indeterminate, the [COMPANY_003] test may be performed and, if negative, the subject may be randomized int o the study, however re -training of the  applicable parties at the site 
and/or central laboratory level should be considered . 
Subjects  who have had household contact [CONTACT_4490] a person with active tuberculosis are 
excluded, unless appropriate/documented prophyla xis for tuberculosis was administered . 
58 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
[IP_ADDRESS].  Chest Radiography  
Chest radiography to include two views (anterior -posterior and lateral) will be obtained 
during the Screening Period in all subjects . If an adequate chest radiography has been 
performed  within 3 mont hs (12 weeks)  prior to the Screening Visit  and documentation 
(including interpretation  of TB status ) is available and is provided to the Investigator to 
review and  file in the subject’s file , that radiography may be utilized to determine 
eligibility of the  subject . To be considered eligible for the study, the radiography must be 
negative fo r active tuberculosis infection; however the Investigator may decide to exclude 
the subjects based on clinically -significant chest radiography findings other than 
tubercu losis (e.g., due to an acute or chronic inflammatory process), according to his/her 
judgment.  
[IP_ADDRESS].  Urinalysis  
Urine samples to assess bilirubin, occult blood, color, glucose, ketones, leukocyte 
esterase, nitrite, pH, protein, specific gravity, turbidity, and urobilinogen, as well as for a 
microscopic exam ( in case of positive macroscopic findings  only) will be obtained under 
fasted conditions  according to the schedule summarized in Table 1.  
 
3.
5.6.24.  Pharmacokinetic Procedures  
[IP_ADDRESS].1.  Blood Samples  for Pharmacokinetic  Assessments 
Blood samples for the quantification of plasma JTE-[ADDRESS_1066964] dose of study drug prior to the PK sample collection , 
as well as the sample collection date and time will be documented for PK data analysis. 
Refer to the laboratory manual for specific instructions for the collection, processing, storing and shippi[INVESTIGATOR_776802]. 
[IP_ADDRESS].2.  Analysis  of JTE- 051 in Plasma  
JTE-051 in plasma will be analyzed using a validated LC -MS/MS method. 
The laboratory performing the JTE-051 plasma concentration assessments will be unblinded to facil itate analysis of  only the samples from the JTE-051- treated subjects . 
Plasma samples from placebo  subjects may be analyzed  as needed.  
59 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.5.7.  Clinical Institutions and Laborator ies 
This study will be conducted by: 
60 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.6. Adverse Events 
3.6.1.  Safety Definitions 
Akros complies with the following International Conference on Harmonisation ( ICH) AE 
definitions: 
Adverse Event: An AE is any untoward medical occurrence in a patient or clinical 
investigation subject admin istered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated  with the use of a medical (investigational) product, whether 
or not related to the medical (investigational) product.  
Serious Adverse Event: As provided by [CONTACT_776844], a n SAE is any adverse drug 
experience occurring at any dose that results in any of the following outcomes: 
• death  
• a life -threatening adverse drug experience 
• inpatient hospi[INVESTIGATOR_1081]  
• a persistent or significant disability/incapacity  
• a congenital anomaly/birth defect  
• other important medical ev ent 
Note:  Important medical events that may not result in death, be life -threatening, or 
require hospi[INVESTIGATOR_3767] a serious adverse drug experience when, based 
upon appropriate medical judgment, they may jeopardize the patient or subject or may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convul sions 
that do not result in hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
Adverse Reaction: All noxious and unintended responses to an investigational medicinal 
product (IMP) related to any dose administered.  
Note: The phrase "resp onses to a medicinal product" means that a causal relationship 
between the medicinal product and an adverse event is at least a reasonable possibility, 
i.e., the relationship cannot be ruled out. 
Unexpected Adverse Drug Reaction: An adverse reaction, the nature (specificity) or 
severity of which is not consistent with the applicable product information 
(e.g., Investigator's Brochure). 
Death:  Death represents an outcome and a SAE criterion, not an event term . The medical 
condition with the fatal outcome should be reported unless the cause of death is unknown, 
in which case the term “Death” is acceptable.  
61 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Inpatient Hospi[INVESTIGATOR_059] /Prolongation of Hospi[INVESTIGATOR_059] : Any admission (even if  
less than 24 hours) to a healthcare facility. Admission also includes trans fer within the 
hospi[INVESTIGATOR_4591]/intensive care unit  (e.g., medical floor to the coronary care unit) . 
Initial and prolonged hospi[INVESTIGATOR_776803]/or convenience reasons (e.g., lack of personal care at home, unable to 
transfer to non- acute facility), admission to rehabilitation /hospi[INVESTIGATOR_6125]/skilled nursing  
facilities, emergency room visits, same -day/outpatient/ambulatory procedures, and those 
for pre -planned, elective procedures for a pre -existing condition that did not worsen after 
the informed consent has been signed (no AE present) . However, if the hospi[INVESTIGATOR_776804] a complication of a pre -existing condition, the complication 
(diagnosis of same) would qualify as an SAE. 
Disability: A substantial disruption of a person’s ability to conduct normal life functions. 
Life-threaten
ing: Any adverse drug experience that places the patient or subject, in the 
view of the I nvestigator, at immediate risk of death from the reaction as it occu rred, i.e., it 
does not include a reaction that had it occurred in a more severe form, might have caused 
death.  
Physic
al Examination,  Vital Signs, Laboratory Test and 
ECG Abnormalities:  Any abnormalities fulfilling the criteria fo r an SAE should be 
reported as such, in addition to being recorded as an AE in the CRF. Any abnormal vital sign, physical   finding or laboratory/ECG result which is 
clinically significant (i.e., meets one or more of the following co nditions) should be 
recorded as a single diagnosis on the AE page in the CRF: 
• Accompanied by [CONTACT_4659]  
• Leads to permanent discontinuation of study drug 
• Requires a change in concomitant therapy (e.g., addition of, interruption of, 
discontinuation of, or any other change in a concomitant medication, therapy or 
treatment ). 
This does not apply to abnormal vital signs, physical finding or laboratory/ECG results that do not meet the clinical significance criteria or those which are a result of an AE which  has already been reported.  
Pre-existing conditions that are detected at the Screening Visit  (Visit 1),  including 
abnormalities in ECG, physical examination, n  vital signs, and 
laboratory tests, are considered to be medical history.  
3.6.2.  Assessing Adverse Events  
When completing appropriate forms for reporting the AE, the Investigator will be asked to assess the AE as follows:  
Seriousness of Adverse Event : 
• Serious: The AE meets a criterion of the SAE definition.  
• Not Serious: The AE does not meet a criterion of the SAE definition.  
62 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Severity  of Adverse Event :  
• Mild : No interference with functioning. 
• Moderate: No significant interference with functioning.  
• Severe: Significant interference with functioning.  
Relationship of Adverse Event  (Causality):   
The Investigator’s causality assessment is the determination whether there is a reasonable 
possibility  that the IMP caused or contributed to the adverse event. Generally, the facts 
(evidence) or arguments to suggest causal relationship should be documented. Factors to 
be taken into consideration when assessing causality include: subject’s underlying and 
pre-existing conditions, prior/concomitant medications, timing of onset relative to study 
drug administration , the known PK characteristics of JTE-051, the currently -known safety 
profile of JTE -051, known class effects of similar MOA drugs, the 
de-challenge/re- challenge response (if available) and any other information that is 
considered relevant by [CONTACT_737]. 
Akros Pharma Inc. evaluates the relat ionship of an AE to the study drug using the 
following three categories : 
• Not R elated   
• Possibly Related  
• Related  
Action Taken with Regard to S tudy D rug: 
Akros Pharma Inc. evaluates the action taken with the treatment product and/or interacting product using the following four definitions: 
• Dose Not Changed:  The subject was on treatment with the study drug when the 
AE occurred, and the study drug dosing was maintained at the same dose level 
• Drug Interrupted: The subject was on treatment with the study drug when the 
AE occurred, and the study drug dosing was temporarily discontinued and then re-started  
• Drug Withdrawn:  The subject was on treatment with the study drug when the 
AE occurred, and the study drug dosing was permanently discontinued  
• Not Applicable:  The subject  was not receiving treatment with the study drug 
when the AE  occurred (i.e., AE  occurred before the first study drug 
administration or  after the last study drug administration)  
Other Action Taken:  
• None 
• Additional Treatment Given for the AE  
• Therapeu tic/ Diagnostic Procedure  
• Other  (including discontinuation/reduction of a concomitant medication  due to 
the AE )  
63 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Outcome to Date:  
• Not Recovered/Not Resolved: The subject  has not yet recovered from the AE; 
the event has not improved (follow -up of all serious AEs will be continued 
until the overall clinical outcome has been ascertained).  
• Recovering/Resolving : The subject has not yet recovered from the AE, 
however, the event is improving (follow -up of all serious AEs will be 
continued until the overall clinica l outcome has been ascertained).  
• Recovered/Resolved : The subject recovered from the AE with no sequelae. 
• Recovered/Resolved with Sequelae: The subject recovered from the AE with 
sequelae.  
• Fatal: The subject’s death was a result of the AE.  
3.6.3.  Reporting Adverse Events  
Adverse Events Reporting   
Adverse events  occurring (initial occurrence or a worsening of a pre -existing condition) 
after the informed consent has been signed  and up to 4 weeks ( 28 days) after the last dose 
of study drug will be reported and included in the study database. However, pre -existing 
conditions detected as part of the screening procedures  should be documented as medical 
history. A dverse events  will be reported on the AE CRF page.  
Serious Adverse Event Reporting 
Reporting by [CONTACT_776845]. A brief, non- all-inclusive summary is provided below. 
Any SAE experienced by a study subject after signing the informed consent to [ADDRESS_1066965] dose of study drug will be reported to the Sponsor or designee . Additionally, 
SAEs that occur after this period will also be reported to the Sponsor or designee if the 
Investigator considers the SAE related  to the study drug. 
Serious adve rse events  (both initial reports  and follow- up information) must be reported 
to the Sponsor or designe e within 24 hours of the Investigator’s (site’s) awareness or 
notification of the event. 
The Investigators should make every effort to provide complete information when 
reporting the SAE  (both for initial reports, as well as for follow-ups).  
The Investigator must continue to follow the subject until the SAE has subsided, the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairm ent), or 
the subject dies. Within [ADDRESS_1066966] submit it to the Sponsor or designee. 
The Investigator is also required to submit SAE reports to the IRB/IEC in accordance 
with local requirements. All in vestigators involved in studies using the same IMP  will 
64 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
receive any Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R) reports for 
onward submission to their local IRB/IEC as required. All reports sent to investigators 
will be blinded. 
Reporting by [CONTACT_776846]/IECs will be informed by [CONTACT_776847]. Additionally, all S[LOCATION_003]Rs will be reported 
by [CONTACT_776848], as appropriate . Cases will be 
unblinded by [CONTACT_776849]. 
Exposure in Utero  Reporting:  
If a female subject becomes pregnant or the female partner of a male subject participating 
in the study becomes pregnant after the subject receives  the first dose  of study drug , or 
within [ADDRESS_1066967]/ partner should be followed by [CONTACT_776850]. If the pregnancy ends for any reason before the anticipated date, the 
Investigator should notify the Sponsor or designee. At the completion of the pregnancy, the Investigator will document the outcome of the pregnancy. If the outcom e of the 
pregnancy meets the criteria for immediate classification as an SAE (i.e.,  spontaneous 
abortion, stillbirth, neonatal death, or congenital anomaly), the Investigator should follow the procedures for reporting an SAE as described above. 
Overdose  Reporting:  
An overdose is a significant variation from the recommended/scheduled dosage for a product. For the purposes of this study, overdose is defined by  [CONTACT_776851] a day. If such situatio ns occur, 
the Investigator should provide additional training to the subject on study drug dosing 
instructions and emphasize the importance of compliance. Currently there is no known 
antidote to JTE -051, thus appropriate symptomatic and/or supportive care is to be 
provided at the I nvestigator’s discretion, as needed. The subject’s continued eligibility 
will be left to the judgment of the  Investigator. 
Information on overdoses in subjects is collected by [CONTACT_16015]. Should a subject experience an overdose during the course of the study, the investigator or qualified designee must report the overdose as soon as possible, but not later than the 
timeframe requested by [CONTACT_776852]. Instructions will be provided on how to 
collect this information.  
65 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
3.7. Identification of Treatments  
3.7.1.  Method of Assigning Subjects to Treatment Groups  
At the Screening Visit (Visit 1 ), each site will assign potential study subjects  an 
eight-character  subject  number. This number will consist of a four- digit site number  (with 
the first two digits representing the country- specific number  and the next  two digits 
representing the site -specific number ) and a three- digit subject  number assigned i n a 
sequential manner . The hyphen between the site and subject number  will account for the 
eight h character.  This number will represent the subject ’s identifier throughout the study. 
Following confirmation of eligibility at Visit 2 , the Interactive Web Res ponse System 
(IWR S) will be contact[CONTACT_776853]  a four -digit 
randomization number that will correspond to a randomly assigned treatment group. 
3.7.2.  Identity of Investigational Products   
 
3.7.
3. Storage and Handling Procedures  
The JTE-051 and placebo  tablets should be stored  at room temperature between 20 and 
25°C ( [LOCATION_002] Pharmacopeia [ USP]) and in a secure location with restricted access .  
3.7.4.  Clinical Supplies Packaging  
Each site will receive a supply of double -blind study drug packaged as blister cards  
corresponding to [ADDRESS_1066968] s may  be labeled with the following information , as app ropriate : 
• Sponsor identity and protocol number 
• Card  number 
• Dosing instructions 
• Spaces for site personnel to add subject  number and subject initials  
66 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
• Spaces for site personnel to add visit number, site number, and Investigator name 
• Spaces for site personnel to add the card identifier, as appropriate 
• Quantity and identity of contents 
• Lot number and storage conditions 
• Expi[INVESTIGATOR_320] 
• For investigational use only statement 
The planned blister card allocation of tablets for each dose, broken down by [CONTACT_6490], is provided below. 
Treatment 
Group  Tablet 1  Tablet 2  Tablet 3 Tablet 4  
JTE-051 50 mg  JTE-051 50 mg JTE-051 Placebo JTE-051 Placebo JTE-051 Placebo 
JTE-051 100 mg  JTE-051 50 mg JTE-051 50 mg JTE-051 Placebo  JTE-051 Placebo  
JTE-051 150 mg  JTE-051 50 m g JTE-051 50 mg  JTE-051 50 mg  JTE-051 Placebo  
JTE-051 200 mg  JTE-051 50 mg  JTE-051 50 mg  JTE-051 50 mg  JTE-051 50 mg  
Placebo  JTE-051 Placebo  JTE-051 Placebo  JTE-051 Placebo  JTE-051 Placebo  
3.7.5.  Administration of Study Drug  
During the Treatment  Period , beginning on the day of Visit 2, subjects  will 
self-administer  one dose  of study drug (4 tablets) daily  for [ADDRESS_1066969] should only be utilized by [CONTACT_776831] -supplied (non- back -up) bli ster cards has been used.  
Randomized subjects will receive two study drug blister cards at Visits [ADDRESS_1066970] (identical in appearance with the 
other blister cards) for use as needed throughout the study. The back- up blister card may 
be identified at the site level and subjects will be instructed to utilize all tablets from the other (non- back -up) blister car ds before initiating tablet use from the back -up blister card. 
The subjects  will be instructed to return the clinical supplies (full, partially full, and 
empty blister cards , including the back- up blister card ) at Visits 3, 4, [ADDRESS_1066971] will be re -dispensed at Visits 3 through 
5 and will be collected at Visit 6 along with all non- back -up blister cards. 
67 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066972] responsibility for the control and proper distribution of all study drug (including any investigation al product or reference product ) in accordance 
with this protocol. The Investigator is responsible for ensuring that all study drug will be 
stored at the site at recommended storage t emperatures and conditions, in a secured area, 
free of environmental extremes, with restricted access. The Investigator also ensures that all study drug will be dispensed only to study subjects  who have provided written 
informed consent and have met all entry criteria.  
Study drug accountability will be performed by [CONTACT_776854], according to the schedule of procedures presented in 
Table 1. Study drug compliance will be assessed and documented per GCP . 
3.7.7.  Randomization 
Approximately 250 eligible  subjects with active RA will be randomized into this study. 
Subjects  will be randomized in a 1:1:1:1:1  ratio ( [ADDRESS_1066973] s per treatment group) to 
receive JTE- 051 50 mg, JTE -051 100 mg, JTE -051 150 mg, JTE- 051 200 mg  or placebo 
once daily. R andomization will be stratified by [CONTACT_776855]-CRP level  
(the qualifying hs- CRP value must be utilized) . 
An IWR S will be employed for the randomization activities. It will use a stratified 
randomization algorithm that takes into account the strata  specified above.  
The randomization code will be controlled by [CONTACT_776856] s, see 
Section  3.7.8.  
3.7.8.  Blinding  
This study is double -blind (i.e., the treatment assigned to each subject  will not be 
disclosed to the Sponsor members or designees involved in the study, study staff at the 
site or to the subject ). The JTE-051 50 mg tablets , as well as the placebo tablets will be 
supplied as unbranded tablets which are identical in appearance.  
The laboratory performing the JTE- 051 plasma  concentration assessments will be 
unblinded to facilitate a nalysis of only the samples from the JTE -051- treated subjects. 
Plasma samples from placebo -treated subjects  may be analyzed as needed  (see 
Section  [IP_ADDRESS]). 
3.7.9.  Breaking the Blind 
The study drug  code may be broken by [CONTACT_13177] a particular subject  only in the 
event of a serious  adverse experience, which the Investigator feels cannot be adequately 
68 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066974]  the Sponsor’s Medical Monitor prior to breaking the code. If this 
is not possible and the situation is an emergency, the Investigator may break the blind to 
identify the treatment assignment for the specific subject  only and must contact [CONTACT_429]’s Medical Monitor as soon as possible thereafter. The Sponsor may also elect to 
break the blind for cause. If the blind is broken, appropriate documentation should be 
completed as soon as possible. 
Additionally, breaking of the blind may be performed by [CONTACT_776857], as appropriate.  
3.8. Statistical Methods  
This section provides an abbreviated statistical analysis plan (SAP) for the efficacy and 
safet y parameters. A formal SAP will be developed at a later time. Statistical issues not 
addressed in the present section may be developed in the formal SAP. The plans outlined 
in this section may be modified in the SAP; however, any major modifications of the  
primary endpoint definition and/or its analysis may also be reflected in a protocol amendment, as appropriate. Other deviations to the SAP will be discussed in the study report. 
3.8.1.  Subject Population for Analysis  
[IP_ADDRESS].  Randomized Population 
The randomized populati on consists of all subject s who are randomized at Visit 2 to one 
of the five treatment groups: JTE-051 50 mg QD, 100 mg QD, 150 mg QD , 200 mg  QD 
and matching placebo QD. 
[IP_ADDRESS].  Safety Population 
Safety population consists of the randomized subject s who receive at  least one dose of the 
study drug (the actual received drug will be considered) .   
[IP_ADDRESS].  Intent -To-Treat (ITT) Population 
The ITT population consists of the randomized subjects  who receive at least one dose of 
the study drug per randomization. [IP_ADDRESS].  Per Protocol (PP) Population 
The PP population is a subset of the ITT population in which subject s do not have any 
major protocol deviations. A pre -analysis meeting will take place aft er all data have been 
entered into the database and cleaned, but before the release of the randomization code, to 
identify the PP population. The decisions made to select the PP population will be 
documented. 
69 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
[IP_ADDRESS].  Pharmacokinetic Population 
The PK population consists of the randomized subject s who receive at least one dose of 
JTE-[ADDRESS_1066975] one usable JTE-051 plasma concentration measurement.  
[IP_ADDRESS].  Sample Size 
Approximate ly [ADDRESS_1066976] s (50 in each treatment group) will be randomized into 
the DB treatment period of  this study.   
The primary efficacy evaluation will be to compare the ACR [ADDRESS_1066977] a statistical significant difference at the 5% level with about 80% 
power (using 2- sided Fisher’s exact test):  
  
  
About [ADDRESS_1066978] an 80% power for a 
range of placebo responses. The sample size calculation was carried out us ing the 
software SiZ 6. 2 (Cytel Inc., 2013).  
3.8.2.  Interim Analysis  
No interim analysis is planned for the study. 
3.8.3.  Efficacy Analyses  
The ITT population will be used for all efficacy data analysis. The analysis of the primary 
efficacy parameter will be repeated on  the PP population if it excludes 20% or more of 
the subject s from the ITT population. Additional efficacy parameter analyses using the PP 
population and/or other sub-population may be performed if deemed appropriate.  
[IP_ADDRESS].  Efficacy Parameters  
The primary effic acy parameter  is the ACR20 response rate at  EOT.  
The secondary efficacy parameters are (evaluated at  Weeks 2, 4, 8, 12 and 16 
respectively , unless otherwise stated): 
• Percentage of subjects achieving ACR20/50/70 response rate  
• Change from baseline in SDAI 
• Percent age of subjects who achieved remission based on SDAI (≤3.3)  
• Percent age of subjects who achieved low disease activity based on SDAI (≤11)  
• Change from baseline in CDAI 
• Percent age of subjects who achieved remission based on CDAI (≤2.8)  
• Percent age of su bjects who achieved low disease activity based on CDAI (≤10)     
• Percentage of subjects achieving Boolean Remission 
• Change from baseline in DAS28- CRP  Placebo ACR20  0.25 0.35 0.45 
Sample size per group  47 48 47 
70 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
• Percentage of subjects with DAS28 -CRP of <2.6  
• Percentage of subjects with DAS28 -CRP of <3.2 
• Percent age of subjects with good EULAR response at Week 12 
• Percent age of subjects with moderate EULAR response at Week  12 
• The ACR -N index 
• Change from baseline in HAQ- DI 
• Change from baseline in the number of tender and swollen joint counts  (68/66 
joints will be counted) 
• Change from baseline in subject  pain score by [CONTACT_37224]   
• Change from baseline in SGA of disease activity by [CONTACT_37224]  
• Change from baseline in PGA of disease activity by [CONTACT_37224]  
• Change from baseline in hs- CRP  
3.8.3.
2. Efficacy Data Analysis 
For the purpose of efficacy analysis, t he EOT value is defined as the last value taken  
during the  DB treatment period after the first do se of study drug without any treatment 
intervention. For subject s who receive rescue treatment, the last value prior to the 
interv ention will be defined as the EOT. 
For the primary efficacy parameter (ACR20 at EOT), the Fisher’s exact test will be used 
to compare each JTE -[ADDRESS_1066979] JTE-051 dose , etc.  
For dichotomous secondary efficacy parameters, similar analyses as the primary efficacy parameter will be used by [CONTACT_776858], i.e., the Fisher’s exact test  for pairwise comparisons 
with placebo and the Cochran- Armitage test for trend.  
 
71 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066980].  
All analyses will be performed two -sided at the 5% significance level. No formal multiple 
comparison adjustment will be made, therefore results should be interpreted with the 
multiplicity in mind. The estimated treatment effect (relative to placebo) from the model , 
along with a two -sided 95% CI  and p-value, will be tabulated  where appropriate . The 
Newcombe’s  CI of the rate difference
28 between JTE -051 dose and placebo will be 
computed when performing the Fisher’s exact test. Graphical presentations of the 
treatment profile may be depi[INVESTIGATOR_1230]. Sensitivity analysis, model fit assessment may be conducted and data transformation may be employed if appropriate. 
Descriptive statistics of efficacy parameter s over time will be presented  by [CONTACT_3148] . 
They will include the number of subjects  (N), arithmetic mean, standard deviation ( SD), 
median, minimum and maximum  for continuous parameters, and in frequency tabulation 
form for dichotomous parameters. 
72 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066981] will be 
included in the analysis model where appropriate. 
[IP_ADDRESS].  Treatment by [CONTACT_776859] -by-baseline effect is not considered, however the baseline will  be included 
in the respective parametric analysis model of the efficacy parameters where appropriate.  [IP_ADDRESS].  Subgroup Analysis  
Subgroup analyses may be performed if appropriate. [IP_ADDRESS].  Handling of Dropouts or Missing Data 
Some efficacy parameters are a composite value derived from a complex instrument. The 
chance that on e of its components is missing increases greatly due to various reasons. In 
order to minimiz e missing data, algorithms will be prepared to compute the derived value 
where reasonable in case some of the components are missing. These algorithms will be descr ibed in the SAP. 
There will be missing data however, either intermittent like a missing visit or due to subject  dropout. For dichotomous efficacy parameters analysis by [CONTACT_7206], subject s 
with missing data will not be included in the analysis. For analysis with multiple time points, any missing data will be imputed using the last observation carried forward (LOCF) method except for subject s who withdraw for reasons related to treatment. In the 
latter case, any value after withdrawal will be imputed as treatment failure. For parameters analyzed both by [CONTACT_776860], these two approaches would strengthen the findings when they are similar. 
For continuous efficacy parameters, no imputation will be employed. This is because the 
mixe d effect model gives valid estimates if the missing data mechanism is “missing at 
random”, a common assumption made as the first approach for analysis. 
73 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Other missing data imputation methods may be employed for additional sensitivity 
analysis if deemed necessary.  
3.8.4.  Safety Analyses  
The safety population will be used for the safety data analysis unless otherwise stated. 
[IP_ADDRESS].  Safety Parameters  
The safety parameters are:  
• Adverse events  
• Clinical laboratory safety tests  
• Vital signs, ECG parameters  
[IP_ADDRESS].  Safety Data Analysis  
Descriptive statistics of vital signs, ECG parameters, and clinical laboratory data will be 
presented by [CONTACT_776861] N, arithmetic mean, SD, median, minimum 
and maximum, or in frequency tabulation form as appropriate. For continuous param eters, change from baseline will be summarized by [CONTACT_776862]. 
Potentially clinically significant values for vital signs, ECG, and laboratory data will be flagged in data listings and may be summarized as appropriate.  
All safety data will be p resented in the data listings, and will be flagged for events of 
interest (e.g., out of range laboratory data) as appropriate. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities  
(MedDRA) and will be summarized by [CONTACT_695105].  
Other safety parameters will be summarized as appropriate.  
3.8.5.  Pharmacokinetic Analyses  
The PK population will be used for the PK data analysis unless otherwise stated. 
[IP_ADDRESS].  Pharmacokinetic Parameters  
The PK measurements are:  
• Trough concentrations (C
trough) of JTE -051 will be measured at each visit during 
the Treatment Period;  
• Population PK parameters for JTE -051 may be generated using population PK 
analysis.  
[IP_ADDRESS].  Pharmacokinetic Data Analysi s 
If data allow , population PK analysis will be pe rformed using  plasma concentration data 
of JT E-051. Population estimates of PK parameters of JTE-051 such as the apparent oral 
clearance of drug following extravascular administration  (CL_F ) and apparent volume of 
distribution following extravascular administration (V_F) will be estimated, and intra - 
and inter -subject variability of these parameters will be characterized. The effect of 
demographics/covariates (e.g., age, body weight, gender, race, use of concomitant 
74 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
medications) on the pharmacokinetics of J TE-051 will be evaluated. Other PK parameters 
will be determined and reported as deemed appropriate.  
The relationship between exposure of JTE -051 and response (e.g., efficacy) may also be 
explored . Descriptive statistics  of plasma concentration data for J TE-051 will be 
presented  by [CONTACT_776863] N, arithmetic mean , geometric mean,  SD, coefficient of 
variation  (CV%), median, minimum and maximum. 
The population PK analysis results may be reported in a separate report. 
3.9. Quality  Control and Quality Assurance 
This study will be conducted in compliance with the protocol, GCP  as defined by [CONTACT_776864] (CFR) 21 parts 50, 56 and 312, Sponsor /designee policies 
and procedures and all applicable local and national regulations. 
The following steps  will be taken to ensure the accuracy, consistency, completeness, and 
reliability of the data: 
a) Routine site monitoring; 
b) CRF review against source documents;  
c) Data management quality control checks;  
d) Statistical quality control checks; 
e) Continuous data acquisition and cleaning; and 
f) Quality control of final report. 
A representative from the Sponsor and/or authorized representatives may conduct 
periodic audits of the clinical site s and study processes, including, but not limited to, the 
clinical database and the final report. The study may also be subject to inspection by 
[CONTACT_12721]. The Investigator hereby [CONTACT_776865]. 
4 I NVESTIGA TOR OBLIGATIONS  
4.1. Institutional Review /Independent Ethics Committee  
An Investigator shall ensure that an IRB /IEC that complies with the requirements set 
forth in the US CFR 21 Part 56 or in the applicable local regulations for  countries outside  
US, as appli cable, will be responsible for the initial and continuing review and approval 
of the proposed clinical  study. The Investigator shall also assure that he or she will 
promptly report to the IRB /IEC all changes in the research activity and all unanticipated 
problems involving risk to human subjects or others, and that he or she will not make any 
changes in the research without IRB /IEC approval, except where necessary to eliminate 
apparent immediate hazards to human subjects. 
All advertisements used in conjunction with this study must be reviewed and approved by 
[CONTACT_776866] /IEC, if applicable. The IRB /IEC’s 
75 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066982] a copy of the IRB /IEC approval document to the Sponsor or designee.  
The Investigator will not begin the study until the Sponsor or designee  has authorized 
release of investigational drug product. 
Any amendments to the protocol must be approved in writing by [CONTACT_1201] /IEC prior to 
implementation by [CONTACT_737] . However, any change to the protocol to eliminate an 
apparent immediate hazard to the subjects may be implemented immediately, provided 
that the IRB is subsequently notified in accordance with the US 21 CFR Part 56.104 (c) 
or the applicable regulations in countries outside US. 
The Investigator will also provide the IRB /IEC with a current copy of the IB at the start of 
the study, as well as an updated version of each  if revised during the study. 
A progress report will be  submitted by [CONTACT_26492] /IEC at intervals 
established by [CONTACT_1201]/IEC. The Investigator will retain a copy of this report in the 
Investigator’s Documentation File. After completion or termination of the study, the Investigator will submit a  final documentation to the IRB/IEC. A copy of all  reports will 
be sent to the Sponsor or designee. 
4.2. Subject Consent  
In obtaining and documenting informed consent, the Investigator should comply with the 
appli cable regulatory requirement(s), i.e., US [ADDRESS_1066983] the IRB /IEC written approval of the 
written informed consent form and any other written information to be provided to subjects.  
The written informed consent form and any other written information to be provided to subjects must be revised whenever important new information becomes available that may be relevant to the subject’s consent. Any revised written informed consent form, and written information must receive the IRB /IEC approval in advance of use. The subject or 
the subject’s legally acceptable representative must be informed in a timely manner if new information becomes available th at may be relevant to the subject’s willingness to 
continue participation in the trial. The communication of this information should be documented. 
The Investigator, or a person designated by [CONTACT_737], should fully inform the 
subject or, if the subject is unable to provide informed consent, the subject’s legally acceptable representative, of all pertinent aspects of the trial including the written information and the approval by [CONTACT_1201] /IEC. A copy shall be given to the person signing 
the form.  
76 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
4.3. Data  Collection  
It is the Investigator’s responsibility to ensure that data are collected and reported 
according to the study protocol. The Investigator will ensure the accuracy, completeness, and timeliness of the data reported on the CRF and in all required reports.  
Additionally, laboratory data may  be received by  [CONTACT_776867] . These data files may be merged with 
the clinical database.  
4.3.1.  Case Report Forms  
Electronic CRFs will be produced according to protocol requirements, and access /training 
will be provided to the site  in order for the r esearch staff to record the data obtained on 
each subject during the study.  The CRFs must be completed for each subject randomized in the study  and will be 
reviewed by [CONTACT_776868]. The CRFs must 
be kept up- to-date so that they always reflect the latest observations on the subjects 
enrolled in the study. All records should be kept in conformance to applicable  national 
and local laws and regulations. 
4.3.2.  Source Documents  
It is the responsibility of the Investigator to collect and record all study data on source 
documents. The Investigator must provide access to source data/documents for 
study-related monitoring, audits, IRB /IEC review, and regulatory inspection. 
4.4. Adherence to Protocol  
By [CONTACT_776869], the Investigator confirms in writing that he/she has read, understands and will strictly adhere to the study protocol. This study will be conducted in accordance with GCP regulations. Additional information regarding 
management of protocol amendments can be found in Section  5.2. 
4.5. Reporting Adverse Events  
For details regarding AE and SAE reporting, see Section  3.6.3. 
4.6. Investigator’s Final Report  
Upon completion of the study, the Investigator will provide the Sponsor or designee  with 
a copy of the summary of the study’s outcome provided to the IRB /IEC. 
4.7. Records Retention  
An Investigator is  required to maintain adequate records of the disposition of the drug, 
including dates, quantity, and use by [CONTACT_1766]. When  the investigation is terminated, 
suspended, discontinued, or completed, the Investigator shall return the unused supplies of the dru g to the sponsor, or otherwise provide for disposition of the unused supplies of 
the drug under the US 21 CFR Part 312.59 and all applicable local regulations . 
77 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
An Investigator shall retain records required to be maintained under this part for a period 
of two years fo llowing the date a marketing application is approved for the drug for the 
indication for which it is being investigated; or, if no application is to be filed or if the 
application is not approved for such indication, until two years after the investigation is 
discontinued and the FDA is notified.  
The Sponsor or designee  should inform the Investigator(s)/institution(s) in writing of the 
need for record retention and should notify the Investigator(s)/institution(s) in writing when the trial related  records are no longer needed. 
Custody of the records may be transferred to another responsible party, acceptable to the Sponsor , who agrees to abide by [CONTACT_44148]. Written notice of transfer must be 
submitted to the Sponsor  or designee. The Investigator must contact, and obtain the prior 
written permission of  the Sponsor prior to disposing of or transferring any study records. 
4.8. Confidentiality  
The Investigator, Medical Monitor, the Sponsor , and its representatives, agree to protect 
the privacy and confidentiality of the protected health information in accordance with applicable laws and regulations.  
Subject medical information obtained by [CONTACT_776870]. The Investigator shall retain all such information, and any other information designated by [CONTACT_776871], or is otherwise of reasonably  confidential nature, in confidence and shall not 
use such information for any purpose ot her than the performance of obligations pursuant 
to the agreement with the Sponsor and designated affiliate s or contractor s, as the case 
may be,  without prior written authorization from the Sponsor. 
At the subject’s request, medical information may be give n to his or her personal 
physician or other appropriate medical personnel responsible for his or her welfare. 
Data generated by [CONTACT_776872] , the Sponsor or designee , and the IRB(s)/IEC(s) 
if appropriate. 
4.9.  Publications  
The Investigator agrees that all data, calculations, interpretations, opi[INVESTIGATOR_776805] , and that the Sponsor  may make any use thereof at its discretion without 
obligation  to Investigator . The Investigator agrees to consider the results as information 
subject to confidential and use restrictions. 
In the event that the study results are published in the scientific literatur e by [CONTACT_1034] , 
acknowledgment will be made to the Investigator(s) in the accepted style, as appropriate. 
The names of the Investigators or their representatives shall not be used by [CONTACT_21411] 
78 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
publications, for advertising, for other commercial purposes, or otherwise, without 
appropriate written permission, unless required by [CONTACT_239539]. 
Individual study center manuscript(s) for publication, text for talks, abstracts of papers, 
poster presentations, and similar material will be submitted to the Sponsor  for review and 
comment prior to publication or disclosure . In order to ensure that the Sponsor  will be 
able to make comments and suggestions where pertinent, material for public dissemination will be submitted to the Sponsor  for review  at least sixty (60) days prior to 
submission for publication, public dissemination, or review by a third party committee. The Sponsor will have sixty (60) days from receipt of such information to review and comment on and discuss the contents thereof with the Investigator. If the Sponsor  
requests, the Investigator will remove any and all confidential i nformation (other than 
study results) prior to submitting or presenting the materials. Upon the Sponsor’s  request, 
the Investigator will delay submitting or presenting the materials for a further sixty (60) 
days to permit the Sponsor  to take necessary actions to protect its confidential 
information, including the filing of patent applications thereon. 
5 S TUDY MANAGEMENT  
5.1. Monitoring 
Monitoring visits will be cond ucted by [CONTACT_776873]. The Investigator will permit the Sponsor and/or 
designated  representative(s) to make regular site visits during the study. The frequency of 
monitoring visits will be agreed upon by [CONTACT_112102]/or designee. At each visit, the 
Investigator and staff will be expected to cooperate with the Sponsor  or designee  for the 
review and verification of protocol compliance, AE  reporting, CRFs, source documents, 
clinical suppl ies and inventory records, and any additional records as may have been 
previously arranged between the Investigator and Akros or designated representative(s).  
The Investigator and/or other designated study personnel are expected to contact [CONTACT_776874]/or questions. 
5.2. Management of Protocol Amendments and Deviations  
With the exception of emergency situations, implementation of any change in the 
protocol that affects the safety of the subjects, t he scope of the investigation, or the 
scientific quality of the study will not be permitted until the Sponsor  and the Investigator 
have approved the protocol amendment and the IRB /IEC responsible for review and 
approval of the study has reviewed and approved the protocol change. 
Implementation of changes that do not affect the safety of the subjects, the scope of the 
investigation, or the scientific quality of the study cannot be made until the protocol changes are reviewed and approved by [CONTACT_776875]. The IRB /IEC must be 
notified of these protocol changes. 
79 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066984] of the Sponsor  or the Investigator 
with proper and timely notification of all parties concerned. The IRB /IEC will be 
informed promptly and reasons for the termination or suspension will be provided by [CONTACT_3786], as specified by [CONTACT_19712] y requirements. The study can be 
considered complete and/or terminated after the Sponsor or designee  has received the 
following data and materials: 
• Laboratory findings, clinical data, and all special test results from screening through 
the end of the follow-up 
• CRFs  properly completed by [CONTACT_108897] ( including correctly 
answered and closed system or manually -generated edit checks) and signed by [CONTACT_3786] 
• Completed Drug Accountability Records 
• Statement of outcome for each SAE reported  
• Approval/notification of protocols and protocol amendments from IRB /IEC as well as 
relevant health authorities (if applicable)  
5.4. Sponsor’s Final Report  
A final report will be prepared by [CONTACT_175227] a designee at the conclusion of this 
clinical study.  
80 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066985], et al. 2010 
rheumatoid arthritis classification criteria: an American College of  
Rheumatology/European League Against Rheumatism collaborative initiative. Ann 
Rheum Dis . 2010 Sep;69(9):1580-8. 
2. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United 
States , Part I. Arthritis Rheum . 2008 Jan;(58):15-25. 
3. Lee DM, Weinblatt ME. Rheum atoid arthritis . Lancet . 2001 Sep;( 358):903-11. 
4. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Wil liams CA, et al. The 
mortality of rheumatoid arthritis. Arthritis Rheum . 1994 Apr;(37):481-94. 
5. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D , Burmester G, et al. 
Treating rheumatoid arthritis to target: recommendations of an international task  
force. Ann Rheum Dis . 2010 Apr;(69):631-7. 
6. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 re commendations for the use of nonbiologic and 
biologic disease -modifying antirheumatic drugs in rheumatoid arthritis. Arthritis 
Rheum . 2008 Jun 15;( 59):762-84. 
7. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux -Viala C, 
et al. EULAR recommendations for the management of rheumatoid arthritis with 
synthetic and biological disease -modifying antirheumatic drugs. Ann Rheum Dis . 
2010 Jun;( 69):964-75. 
8. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti -tum our necrosis factor alpha monoclonal antibody) versus placebo in 
rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet . 1999 Dec 4;( 354):1932-9. 
9. Klareskog L, van der Heijde D, de Jager J P, Gough A, Kalden J, Malaise M, et al. 
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double -blind randomised 
controlled trial. Lancet . 2004 Feb 28;( 363):675-81. 
10. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti -tumor necrosis factor alpha monoclonal 
antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the A RMADA trial. Arthritis Rheum . 2003 Jan;( 48):35-45. 
11. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double -blind 
randomized controlled clinical trial of the interleukin -[ADDRESS_1066986], 
tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum . 2006 Sep;( 54):2817-29. 
12. Sahu N , August A. ITK inhibitors in inflammation and immun e-mediated disorders. 
Cur Top Med Chem . 2009;( 9):690-703. 
81 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066987]. Altered T ce ll receptor signaling and disrupted T cell 
development in mice lacking Itk. Immunity . 1995 Dec ;(3):757-69. 
14. Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in 
mice lacking the tyrosine kinase ITK. J Immunol . 2003 May 15;170:5056-63. 
 
 
23.
 Aletaha D, Neogi T, Silman AJ, Funovitis J, Felson DT, Bingham CO, et al. 2010 
Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum . 2010 Sep;( 62.9):2569-81. 
24. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; (62):1495-539. 
25. U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009 May 28 (v4.03: 2010 June 14). 
26. Burmester GR , Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, et al.  
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis . 
Ann Rheum Dis . 2013;(72):1445-52. 
27. Agresti A, Categorical Data Analysis. Second Edition. 2012 Dec 03. 
82 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
28. Newcombe R G, Interval Estimation for the Difference between Independent 
Proportions : Comparison of Eleven Methods. Statistics in Medicine . 
1998;(17):873-90. 
29. DAS -score.nl: Disease activity score in rheumatoid arthritis. Available online at: 
http://www.das28.nl/.  
83 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
7 APPENDICES 
 
Appendix 1.  ACR/EULAR [ADDRESS_1066988] Health Assessment Questionnaire© 
Appendix 5.  Efficacy Endpoints Calculation 
 
                        
84 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Appendix 1 . ACR/EULAR Classification Criteria for Rheumatoid Arthritis  
JOINT DISTRIBUTION (0 -5) 
1 large joint  0 
2-10 large joints  1 
1-3 small joints (large joints not counted)  2 
4-10 small joi nts (large joints not counted)  3 
>10 joints (at least one small joint)  5 
SEROLOGY (0 -3) 
Negative RF AND  negative Anti –citrullinated protein ( ACPA ) 0 
Low positive RF OR low positive ACPA  2 
High positive RF OR high positive ACPA  3 
SYMPTOMS DURATION (0 -1) 
<6 weeks  0 
≥6 weeks  1 
ACUTE PHASE REACTANTS (0 -1) 
Normal CRP AND  normal Erythrocyte Sedimen tation Rate  0 
Abormal CRP AND  abnormal Erythrocyte Sedimen tation 
Rate  1 
If the cumulative score is ≥6 = definite RA; when the score is <6 a patient might fulfill 
the criter ia (a) prospectively over time (cumulatively) or (b) retrospectively is data on all 
four domains have been adequately recorder in the past. 
Notes:  
• These are “classification”, not “diagnostic” criteria; the  diagnosis is made by [CONTACT_776876].  
• The target population for the criteria must meet the following two requirements:  
o Patient with at least one joint with definite clinical synovitis (swelling)  
o Synovitis is not better explained by [CONTACT_776877] r eference 23 for additional details pertaining to th ese classification criteria .  
85 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
 
 
86 
Amendment 1, Version 2.0,  Final  – [ADDRESS_1066989] GLOBAL ASSESSMENT OF DISEASE ACTIVITY NRS  TEMPLATE 
   
 
PHYSICIAN’S GLOBAL ASSESSMENT OF DISEASE ACTIVITY NRS  
TEMPLATE 
 
87 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Appendix 4. Health Assessment Questionnaire 
  
 
88 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
 
 
89 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
 
 
90 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
 
91 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Handling Responses  (by [CONTACT_737]) 
For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 
for “Without ANY difficulty,” 1 for “With SOME difficulty,” 2 for “With MUCH 
difficulty,” and 3 for “ UNABLE to do”.  
• The HAQ- DI questionnaire should be completed by [CONTACT_1177], following 
receipt of detailed instructions from the I nvestigator/study staff. After the subject 
completes the questionnaire and prior to the subject leaving the study site, the study staff should perform a detailed review of the answers, discuss why any questions were not answered, and what was intended when answers were marked outside the 
box or more than one box was marked for a question. 
• Each subject should answer the questions according to his/her personal situation. Thus, the ratings, “Without ANY difficulty”, “With SOME difficulty”, “With MUCH difficulty”, and “UNABLE to do”, are deliberately not defined for subjects. For example, if a subject asks what “SOME” means, an appropriate response would be “Whatever you think ‘SOME’ means to you”. 
• When a sub- category item does not apply, e.g., when a subject does not use shampoo 
(or perhaps has no hair), the subject should give the response that represents the ability the subject believes he/she would have had in attempting the activity.  
• When a subject uses aids or devices (e.g., crutches, jar openers), the subject should answer the question based on the usual equipment or way of performing the activity. If the subject has no difficulty doing an activity when using aids/devices, the subject should mark the “Without ANY difficulty” option. In scoring, the use of a ids/devices 
results in an adjusted score for that item.  
• Notes about Aids/Devices:  The assignment of devices to particular disability 
categories assumes that the devices are used only for their intended purposes as shown in Table [ADDRESS_1066990] indicates use of a cane, it is 
presumed that the cane is used as an aid in walking.   If the subject informs the Investigator/site personnel that a device listed is being used for a different activity other than those shown in Table 2, (e.g., a ca ne is 
used for getting up from bed but not walking), or if a different device, not listed on the HAQ -DI form is utilized by [CONTACT_423], then the Investigator must 
confirm for which activity category the specific device is utilized and a device from the list that is specific for that same activity category should be checked. This may be a different device than the one actually used (e.g., “built up or special chair” should be checked instead of “cane” in this example).  
  If a device is used for any activity in the “ACTIVITIES” category, as listed on Page 4 of the HAQ -DI questionnaire, only the “Errands and chores” under 
“HELP FROM ANOTHER PERSON” should be checked (i.e., none of the AIDS and DEVICES listed on Page 4 should be checked). This will ensure the appropriate adjustment to the score for the "ACTIVITY" category (this is done 
programmatically).  
92 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
• Items left blank or multiple answers:  If all component questions are blank or if 
more than one answer is given, then follow -up with the subject at the time of th e 
visit is required.  
• Improperly Marked Items:  If the subject’s mark is outside the answer box, then 
move it to the closest one. If it’s directly between the two, move it to the answer with 
greater difficulty. However, follow -up with the subject and confirmation of intended 
answer should be done at the time of the visit, and all items should be marked appropriately before the subject leaves the study center.  
NOTE: A H
AQ-DI sco
re cannot be calculated validly when there are scores for 
less than six of the eigh t categories.  
Scoring (performed by [CONTACT_1034])  
The HAQ-DI’s scoring conventions allow for the computation of two disability indices: 1. The Standard HAQ -DI is the preferred and traditional scoring method which takes into 
account the use of aids/devices.  
2. The Alternative Disability Index
 does not take into account the use of aids/devices.  
A subject must have a score for at least six of the eight categories. Otherwise a HAQ -DI 
score cannot be validly computed. For the purpose of the current study, the sta ndard 
computing method will be applied. 
Computi
ng the Standard HAQ -DI Score (
With Aids/Devices):  There are three steps:  
1. Sum the
 [ADDRESS_1066991] sub- category score from each 
category  (for example,  in the category “EATING”  there are three sub -category 
items. If a  subject responds with a 1, 2, and 0, respec tively; the category score is 2).  
2. Adjust for use of aids/devices and/or help from another person when indicated. Table 2 identifies the Aid/De vices companion variable for each HAQ -DI category.  
Table 
2. Companion Aids/Device Items for HAQ -DI Cat
egories  
HAQ -DI Category   Companion Item  
Dressing & Grooming  Devices used for dressing  
Arising  Built up or special chair  
Eating  Built up or special utensils  
Walking  Cane walker, crutches , wheelchair  
Hygiene  Raised toilet seat, bathtub seat, bathtub bar  
Long handled appliances in bathroom  
Reach  Long handled appliances for reach  
Grip Jar opener (for jars previously opened ) 
• Adju st the score for a category by [CONTACT_30212] a zero or a one to a two.  
• If a subject's highest score for that sub- category is a two it remains a two, and if a 
three, it remains a three.  
3. Divide the summed category scores by [CONTACT_776878] (must be a minimum of 6) to obtain a HAQ- DI score of 0 -3 (3=worst functioning). 
93 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Appendix 5.  Efficacy Endpoints Calculation 
Numeric ACR (ACR -N) Index  
The ACR -N will be derived  by [CONTACT_776879]  3 through 7 based on the ACR core 
set measures collected b y the Investigator . See Section [IP_ADDRESS] for the description of the 
ACR core set measures assessments by [CONTACT_737].  
This is a continuous variable expressing the percentage improvement from baseline a 
subje ct has experienced, defined as the minimum of percent improvement in swollen 
joints, tender joints and the median percent change in the other five  ACR core s et 
measures : 
1. Subject ’s Assessment of Arthritis Pain.  
2. Subject ’s Global Assessment of Disease Activit y. 
3. Physician’s Global Assessment of Disease Activity .  
4. Health Assessment Questionnaire  Disability Index ( HAQ- DI) 
5. Acute phase reactant ( hs-CRP ) 
Thus, and ACR- N of X means that the subject has achieved a change of at least X% in the 
tender and swollen joint counts and a change of at least X% in the median of the other five other parameters. ACR -N will take a negative value if a there is a worsening in either 
the swollen joint count, tender joint count and the median of the other five ACR core s et 
measures (i.e., a subject can have a negative ACR -N despi[INVESTIGATOR_776806]). 
The ACR20/50/70 Response Rate 
The ACR20/50/70 response rate will be calculated by [CONTACT_776879] 3 through 7 based on the ACR core set measures collected by [CONTACT_737].  
This composite parameter  measures improvement in tender  (68) and swollen (66) joint 
counts and improvement in at least three of the following  five ACR core set measures as 
listed above. The ACR 20/50/70 response rate is a dichotomous variable with a positive (= responder) 
or negative (= non-responder) outcome.   ACR20 is ≥ 20% improvement 
 ACR50 is ≥50% improvement  
 ACR70 is ≥ 70% improvement  
 
94 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Simple Disease Activity Index 
The SDAI will be calculated by [CONTACT_776880]. See Section [IP_ADDRESS].[ADDRESS_1066992] o f 28 joints included in the SDAI scoring. 
The scoring of SDAI will be done as follows:      
  
 
Interpretation of scoring will be done as follows: 
 
Clinical Disease Activity Index 
The CDAI will be calculated by [CONTACT_776880]. See Sectio n [IP_ADDRESS].2 for 
the lis t of 28 joints included in the C DAI scoring.  
The scoring of CDAI will be done as follows:      
 
 Interpretation of scoring will be done as follows: 
 
95 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  
JTE-051 AKROS PHARMA INC . 
Clinical Study Protocol AE051-G- 13-003 
Disease Activity Score (DAS)  2829 
The DAS assessment is a derived measurement with differential weighting given to each 
component. The DAS 28 (CRP) will be calculated by [CONTACT_776881] . See 
Section  [IP_ADDRESS].[ADDRESS_1066993] of 28 joints included in the DAS calculation. 
The components of the DAS 28 arthritis assessment include: 
1. Tender/Painful Joint Count (28) 2. Swollen Joint Count (28) 3. CRP 4. Subject’s Global Assessment of Disease Acti vity 
DAS28(CRP) = 0.56 X √(TJC28) + 0.28 X √(SJC28) + 0.[ADDRESS_1066994](CRP+1) + 0.014 X 
SGA + 0.[ADDRESS_1066995] achieving Boolean Remission  
This secondary efficacy parameter will be calculated by [CONTACT_1034], based on the 
following definition: 
• Tender jo int count (TJC) (28) ≤1 
• Swollen joint count (SJC) (28) ≤1 
• C-reactive protein ≤1 mg/dL  
• Subject’s global assessment (SGA) of disease activity ≤1 (on a 0 - 10 scale)  
EULAR Response Criteria 
The EULAR response criteria will be assessed by [CONTACT_1034]. 
This pa rameter takes  into account both the change in DAS28 between two timepoints, as 
well as DAS28 value at a specific timepoint.  
DAS28 -CRP will be utilized in calculating  the EULAR response in the study subjects.  
DAS28 improvement →  
>1.2 >0.6 and ≤1.2 ≤0.6 
Present DAS28↓ 
≤3.2 good response moderate response no response 
>3.2 and ≤5.1 moderate response moderate response no response 
>5.1 moderate response no response no response 
 
Note: High -sensitivity CRP (hs -CRP) will be utilized in all primary and secon dary 
endpoints calculations    
96 
Amendment 1, Version 2.0,  Final  – 24 Mar 2016  CONFIDENTIAL  